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Abstract 
Breast cancer is a biologically and clinically heterogeneous disease that makes 
clinical management challenging. Cancer genomics can identify underlying candidate 
genetic lesions, but functional studies are required to dissect which changes impact disease 
progression, treatment efficacy, and development of resistance. The generation of 
experimental models that can faithfully reproduce the spectrum of human disease is 
therefore essential. RNA interference (RNAi) is a powerful tool that allows for systematic 
loss of function genetics in mammalian systems. This thesis presents two complementary 
approaches for the development of new mouse models of breast cancer based upon RNAi 
technology. The first experimental chapter describes efforts to build a ‘mosaic’ orthotopic 
transplantation model for the purpose of conducting an in vivo RNAi screen for novel tumor 
suppressor genes relevant to the human disease. A pilot screen led to the identification of 
neurofibromin 1 (NF1) as having a putative tumor suppressor activity in breast cancer. The 
following chapter involves the development of a transgenic RNAi mouse model of human 
epidermal growth factor receptor 2 (HER2) positive breast cancer. This new multi-allelic 
inducible RNAi platform was subsequently used to investigate the efficiency of the tumor 
suppressor gene PTEN (phosphatase and tensin homolog) knockdown in driving disease 
acceleration and to assess its role in tumor maintenance. Taken together, this work extends 
the application of RNAi technology, and identifies new (NF1) and expands upon known 
(PTEN) molecular and genetic interactions underlying the progression and maintenance of 
HER2 positive breast cancer. 
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I. Introduction 
 
BREAST CANCER 
Breast cancer is the most frequently diagnosed cancer in women in the United States, 
with an estimated 226,870 new cases in 2012 (American Cancer Society 2012). Despite the 
fact that recent scientific and clinical advances have led to a constant decline in breast cancer 
mortalities, it remains the second leading cause of cancer deaths with an estimated yearly 
mortality rate of 40,000 patients. The decline can be attributed in part to early detection, 
diagnosis, and surgery, coupled with improvements in postsurgical adjuvant treatments 
including hormonal, cytotoxic and molecular based therapies.  
Breast cancer is a clinically heterogeneous disease, the complexity of which relates to 
the diversity of molecular abnormalities driving the tumorigenic process. This collection of 
diseases displays distinct histopathological features, genetic and genomic characteristics, 
and diverse prognostic outcomes and responses to therapy (Vargo-Gogola and Rosen 2007). 
Currently, there is an ideological shift in the treatment of many cancer types, from an 
approach where the histology and tissue of origin were the guiding principles in the choice 
of therapy towards a strategy involving the identification of oncogenic driver mutations and 
selective treatments in the clinic using specific targeting agents. This paradigm change has 
been enabled by the emergence of next-generation DNA sequencing technologies that have 
allowed for the identification of recurrent genetic aberrations and the concurrent 
development of highly selective inhibitors against the products of genes that are activated 
by these alterations (Bernards 2012). Major advances in the areas of breast cancer disease 
classification and targeted therapy will be briefly discussed below. 
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BREAST CANCER PATHOLOGY AND MOLECULAR PROFILES 
Until very recently, pathological examination was the gold standard for diagnosis in 
breast cancer and its role also encompassed the elucidation of etiology, pathogenesis, 
clinicopathological correlation, and prognostication (Leong and Zhuang 2011). Historically, 
the selection of adjuvant systemic therapy for early breast cancer patients relied on risk 
assessment as delineated by the TNM classification (Dinh et al. 2007). Developed in the 
1940s, the TNM staging system for solid cancers classifies malignant tumors based on the 
size of the primary tumor (T), the involvement of regional lymph nodes (N) and distant 
metastasis (M) (Brierley 2006). Furthermore, the Scarff-Bloom-Richardson grading system 
for breast cancer was developed based on microscopic observations based on tubule 
formation, mitotic activity, and cellular pleomorphism (Bloom and Richardson 1957). 
Subsequent refinement and incorporation into the Nottingham Prognostic Index resulted in 
a robust scoring system that predicted long-term survival for patients (Haybittle et al. 1982). 
Additionally, risk-assessment incorporated both patient-related (such as age and 
menopausal status) and tumor-related prognostic factors (such as tumor size and grade) 
(Gelber et al. 2003).  
Technological advances in molecular biology, and the accompanying realization that 
breast cancer is a heterogeneous group of diseases, has shifted the focus of pathobiology 
towards the improvement of diagnostic tools with increased attention being paid to the 
identification of morphological features and immunohistochemical markers of prognostic 
relevance (Leong and Zhuang 2011). Incorporating the expression status of hormone 
receptors and human epidermal growth factor receptor (HER2) as prognostic factors 
marked the first emphasis towards predictive markers that reflect both the molecular make-
up of the tumors and represent the actual targets for therapies such as tamoxifen and 
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aromatase inhibitors against the estrogen receptor (ER) and the humanized monoclonal 
antibody trastuzumab (Herceptin, Genentech) that targets HER2 (Fendly et al. 1990; Dinh et 
al. 2007). Despite efforts invested towards the identification of other immunohistochemical 
biomarkers to further refine breast cancer diagnosis and treatment, few have proven to be of 
value in multivariate analyses and only ER, progesterone receptor (PR), and HER2 
expression have remained essential components of pathological examination (Leong and 
Zhuang 2011). 
To better understand the phenotypic diversity breast cancers present in their natural 
history and responsiveness to therapy, researchers sought to characterize tumors through a 
detailed interrogation of inter-tumor variation in gene expression patterns (Perou et al. 2000; 
Sorlie et al. 2001). These emerging molecular portraits defined a new clinical and biological 
standard relating back to the different features of normal mammary epithelial biology: 
ER+/luminal-like, basal-like, HER2+ and normal breast, with important implications that 
ER negative breast carcinomas may encompass two biologically distinct subtypes (basal-like 
and HER2+) (Perou et al. 2000). Further refinement by Sorlie and colleagues led to the 
luminal subtype A, luminal subtype B/C, basal-like, HER2+ and normal breast-like 
categories (Sorlie et al. 2001). Moreover, evidence of a relationship between the expression-
based subclasses of breast tumors and patient outcome was established (Sorlie et al. 2001). 
During the past decade, the interpretation of breast tumor biology based on molecular 
profiles has steadily become part of the standard medical vocabulary. In invasive ductal 
carcinomas (IDC), which constitute approximately 80% of all breast cancers, at least four 
molecular subtypes are commonly designated by the following general defining traits: 
luminal (ER+, PR+, and HER2–), HER2 overexpressing (ER–, PR–, and HER2+), basal-like 
(ER–, PR–, HER2, and CK5/6+, EGFR+), and normal breast-like (ER–, PR–, and HER2–). 
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Furthermore, it has been demonstrated that IDC and invasive lobular carcinoma (ILC), the 
second major histological type of breast cancer, present additional differences in global 
transcription programs (Zhao et al. 2004).  
The molecular subtypes of IDC segregate by overall survival, with HER2+ and basal 
subtypes demonstrating the worst prognosis while luminal-A shows the most favorable 
outcome (Perou et al. 2000). However, it has been shown that the prognostic outcomes of 
each type of IDC do not differ when a pathologically complete response to therapy is 
achieved (Carey et al. 2007). These distinct prognostic outcomes may reflect the differential 
responses to chemotherapy and targeted therapies by the bulk of the tumor and sub-
populations of tumor-initiating cells (Al-Hajj et al. 2004). More recently, researchers have 
taken molecular and genomic profiling of breast cancer a step further and looked to define 
intra-tumoral heterogeneity at a single-cell resolution (Navin et al. 2010; Navin et al. 2011). 
Continued progress towards a complete understanding of the many critical aspects of 
tumorigenesis, such as the cell of origin and tumor initiation and evolution from the 
perspectives of intra- and inter-tumoral heterogeneity, will likely provide answers to some 
of these seemingly contradictory phenomenon observed in the clinic. 
 
TARGETED THERAPIES IN BREAST CANCER 
Over the last past few decades, breast cancer mortality dramatically decreased in 
great part due to use of adjuvant systemic therapy (Berry et al. 2005; Berry et al. 2006), 
including chemotherapy for most patients, endocrine therapy for those with ER+ disease, 
and more recently trastuzumab for tumors that overexpress HER2. However, many years 
before the development of trastuzumab, endocrine therapy was the cornerstone in the 
therapeutic repertoire for treatment of metastatic, hormone receptor-positive breast cancer 
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(Montemurro et al. 2012). In fact, androgen deprivation therapy for prostate cancer and 
estrogen deprivation therapy for breast cancer represent two of the earliest targeted 
therapies in solid tumor oncology. While both diseases present an initial stage wherein 
hormone therapy is successful in controlling the disease, either through inhibition of 
endogenous hormone production or through inhibition of hormone receptor signaling, after 
a period of time both cancer types exhibit insensitivity to the effects of the first-line 
treatment option (Oxnard 2012). 
It has been over a century since the first clinical observation that oophorectomy of a 
human patient with advanced breast cancer was effective in treating the disease (Beatson 
1896). Tamoxifen, a selective modulator of ER that competitively inhibits the binding of 
estradiol and consequently disrupts mechanisms regulating cellular replication and 
proliferation, has been in use in the clinic since the 1970s (Jordan and Dowse 1976). 
Application of endocrine therapy in a non-selective manner across patient cohorts results in 
response rates of 30% (Buzdar and Hortobagyi 1998). In advanced tumors positive for both 
receptors response rates increase to 50-70%.  
While tamoxifen was the staple component of breast cancer treatment for many 
years, research to find new strategies for treating tamoxifen-resistant hormone-dependent 
breast cancer led to the development of a new class of agents, aromatase inhibitors, that act 
to reduce estradiol production through adrenal androgen conversion by the aromatase 
enzyme (Harvey 1996). Aromatase inhibitors are also being actively evaluated as prevention 
agents for women with a history of ductal carcinoma in situ (DCIS), as well as for the 
treatment of women considered at high risk for developing primary invasive breast cancer 
(Litton et al. 2012). These early observations in targeted therapy involving mixed responses 
and development of resistance underscored the critical need for a better comprehension of 
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the molecular biology at the source of this clinical diversity and an arsenal of targeted 
therapies to match. 
Since its FDA approval in 1998, trastuzumab has become a key component in the 
treatment of early and metastatic HER2-positive breast cancer (Hudziak et al. 1989; Baselga 
et al. 1996; Slamon et al. 2001), and demonstration of its anti-tumor activity provided the 
proof of principle for therapy targeted to receptor tyrosine kinases (RTKs). A member of the 
epidermal growth factor receptor (EGFR) family, the HER2 protein is a transmembrane 
tyrosine kinase receptor involved in regulation of cell growth, migration, survival and 
differentiation (Yarden and Sliwkowski 2001). Amplification of the gene encoding HER2 
(King et al. 1985), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ErbB2) first 
discovered in 1984 (Schechter et al. 1984), is the most common mechanism leading to 
overexpression of the receptor (Pauletti et al. 1996) and results in the constitutive signaling 
of downstream pathways (Yarden and Sliwkowski 2001). HER2 has been found 
overexpressed in 20-30% of human breast cancers and prior to the advent of HER2-targeted 
therapies, patients with HER2-positive disease had higher risk of recurrence after initial 
therapy and poor prognosis (Slamon et al. 1987; Slamon et al. 1989). 
The EGFR family, which also includes EGFR (HER1), HER3 and HER4, is involved 
in cell-cell and cell-stroma communication through signal transduction whereby external 
growth factors, or ligands, affect the downstream transcription of various genes via the 
phosphorylation or dephosphorylation of a series of transmembrane proteins and 
intracellular intermediates, many of which possess enzymatic activity (Ross et al. 2009). 
Activation of the kinase occurs with ligand biding and subsequent hetero- or 
homodimerization of these receptors. HER2 is capable of acting in a ligand-independent 
manner when mutated or overexpressed (Yarden 2001). Its overexpression in the context of 
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breast cancer, which can range from 2- to greater than 20-fold, has been associated with 
cancer promoting phenotypes including increased cell proliferation, cell motility, tumor 
invasiveness, progressive regional and distant metastases, accelerated angiogenesis and 
reduced apoptosis (Moasser 2007). HER2 signaling has been demonstrated to promote cell 
proliferation through the RAS-MAPK pathway and inhibit cell death through the 
phosphatidylinositol 3’-kinase (PIK3)/AKT/mammalian target of rapamycin (mTOR) 
pathway (Yarden and Sliwkowski 2001). 
In 2012, trastuzumab remained the only approved HER2-targeted therapy in the 
adjuvant setting (Jelovac and Wolff 2012). Data from the first generation of clinical trials 
combining it with various chemotherapy regimens showed significant improvements in 
disease-free and overall survival, and consequently a trastuzumab-containing regimen for 
up to one year is now considered standard for all eligible patients with HER2-positive 
tumors. Trastuzumab has significant clinical benefit in the adjuvant and metastatic setting 
but both de novo and acquired clinical resistance have been observed (Baselga 2001). Second 
generation HER2-targeted drugs are in development and in clinical trials, such as antibodies 
against its external domain (pertuzumab), small-molecule tyrosine kinase inhibitors 
(lapatinib and neratinib), anti-HER2 antibodies conjugated to toxic molecules (trastuzumab-
DM1 or T-DM1), and chaperone antagonists (geldanamycin) (Perez and Spano 2012; Tsang 
and Finn 2012). 
 
MOUSE MODELS OF BREAST CANCER 
Human breast cancer cell lines are used extensively as preclinical models both in 
vitro and in vivo as xenografts. Although cell line models have not proven useful for the 
identification of biomarkers of chemotherapy response, and controversy remains to whether 
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the diversity within the available breast cancer cell lines accurately mirrors the inter-tumoral 
heterogeneity observed in the clinic, there is evidence to suggest that when employed under 
the right framework they can serve as a powerful tool for predicting the clinical 
performance of cancer drugs (Voskoglou-Nomikos et al. 2003; Lacroix and Leclercq 2004; 
Bernards 2012).  
In a recent study, Neve and colleagues reported, after cross-examining the molecular 
profiles and genomic alterations of 51 breast cancer cell lines and 145 primary human breast 
tumors, that when relevant subsets of cell lines are used as a system rather than alone they 
can provide robust platforms for the investigation of the signaling pathways associated with 
therapeutic response (Neve et al. 2006). Furthermore, an argument can be made that 
connections between signaling pathways that have proven critical for the development of 
acquired resistance to targeted therapies are hard-wired in a cell autonomous manner and 
consequently less dependent on microenvironmental factors. Nonetheless, it remains of vital 
importance to complement cell line models with other approaches for predicting drug 
response and studying tumor biology, such as three-dimensional cell culture systems, 
patient-derived mouse xenograft and transgenic models of breast cancer (Bernards 2012). 
 
Xenograft models 
While xenograft models involving human breast cancer cell lines suffer from some of 
the same basic criticisms raised against their use in in vitro studies, seminal publications in 
the field have demonstrated their utility and direct relevance to the human disease. A series 
of studies from Massagué and colleagues have shown that intravenous experimental 
metastasis assays can be used to define metastasis gene signatures that correlate 
significantly with clinical data and provide valuable insights into the molecular biology 
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underlying the metastatic process (Minn et al. 2005; Kim et al. 2009; Zhang et al. 2009). Other 
investigators have also been successful in using xenographs to identify gene signatures that 
correlate with prognostic outcomes (Kluger et al. 2005; Montel et al. 2005). 
The growth of breast cancer cell lines in an in vivo environment allows for 
experiments to incorporate the complex tumor-stromal cell interactions that facilitate 
disease formation and progression (Vargo-Gogola and Rosen 2007). However, the obligate 
use of immunocompromised mice and the resulting absence of an intact immune system 
may have profound effects on the tumor biology (Balkwill et al. 2005). There is increasing 
evidence to suggest the fundamental role of the immune system in various stages of 
tumorigenic transformation (Goswami et al. 2005; Schwertfeger et al. 2006; Shree et al. 2011). 
The transplantation of human tumor cells into a foreign microenvironment and the absence 
of co-evolvement of epithelial and stromal compartments of the tumor may point to some of 
the reasons why testing therapeutics in xenograft models has fallen short of accurately 
predicting treatment efficacy in human patients (Vargo-Gogola and Rosen 2007). Efforts to 
humanize the mouse mammary fat pad, through the reconstitution of tumor-promoting 
immune and fibroblast compartments (Orimo et al. 2005; Proia and Kuperwasser 2006), and 
the use of a panel of subtype xenografts instead of a single cell line, may eventually allow 
for increased predictive power. The application of xenograft transplantation methodology to 
perpetuate and expand breast cancer clinical isolates is a unique alternative to the use of 
human cell lines. While the preserved authenticity of the human genomic landscape and the 
retention of stromal components of patient tumor biology makes this an ideal model in 
design, it is inefficient in practice and access to clinical samples is limited (Vargo-Gogola 
and Rosen 2007). Overall, a better understanding of the role of the immune system, 
microenvironment and the unique traits of human breast cancer molecular subtypes is 
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required before informed changes can be made to improve their strength as preclinical 
models and ultimately overcome the obstacle of inefficient translation of major advances in 
basic cancer research into the clinic. 
 
Transgenic approaches 
 A new era of mammary tumor research was initiated in 1984 by Stewart, Pattengale, 
and Leder’s paper using the mouse mammary tumor virus long terminal repeat (MMTV-
LTR) to promote the expression of the proto-oncogene Myc in the mouse mammary gland 
(Stewart et al. 1984). Since then, genetically engineered mouse models (GEMMs) have 
contributed extensively to our understanding of genes that are involved in the promotion 
and progression of breast cancer.  
The first generation of breast cancer GEMMs were generated by targeting oncogenes 
such a Myc, polyoma virus middle T (PyMT), rat ErbB2/Neu, and Hras to the mammary 
gland using the MMTV-LTR and whey acidic protein (Wap) promoters (Sinn et al. 1987; 
Muller et al. 1988; Guy et al. 1992a; Guy et al. 1992b). These relatively simple transgenic 
models provided tools for examining how these oncogenes contribute to breast 
tumorigenesis, but a greater wealth of information regarding signaling interactions was 
obtained by interbreeding various transgenic strains together (Vargo-Gogola and Rosen 
2007). Further advances in mouse modeling technology, such as the use of tetracycline-
regulatable transgenes, allowed for increased precision and control in the developmental 
timing of the induced changes in gene function (Gunther et al. 2002). Moreover, heightened 
tissue and cell type selectivity was afforded through the adoption of Cre/loxp recombinase-
mediated somatic gene deletion and activation that is driven by promoters with varied 
expression patterns, such as MMTV, WAP or keratin-14 (K14) (Wagner et al. 1997; Jonkers et 
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al. 2001; Wagner et al. 2001; Lin et al. 2004). These advances, that afforded spatial and 
temporal control over loss and gain of gene function, created GEMMs that could begin to 
replicate the development of human breast cancer in vivo.  
In contrast to xenograft transplantation systems, GEMMs are immunocompetent and 
retain the endogenous tissue architecture and microenvironmental cues. Sophisticated 
techniques, such as the application of intravital microscopy in transgenic breast cancer 
models has provided a new window through which to study the processes of angiogenesis, 
inflammation and the many steps of metastatic disease dissemination (MacDonald and 
Chambers 2006; Wyckoff et al. 2007; Egeblad et al. 2008). 
To determine the extent to which GEMMs faithfully reproduce the molecular 
features of the human disease, Perou and colleagues extended their study of the molecular 
profiles of human tumors to the commonly used murine models of mammary carcinoma. A 
comprehensive interspecies analysis, involving the gene-expression profiles for 232 human 
breast cancers and 122 mouse mammary tumor samples obtained from 13 GEMMs, was able 
to identify conserved gene expression features between murine and human tumors. 
Although no single mouse model recapitulated all the features of a given human breast 
cancer subtype, genotype correlated strongly with phenotype in the murine tumors and the 
shared expression features provided a framework from which to build a better 
understanding of how researchers might translate findings in GEMMs to the clinic 
(Herschkowitz et al. 2007). Recent studies have also shown that transplantation of 
transgenic tumors is an effective way of generating large cohorts of mice bearing well-
characterized tumors with defined molecular and genetic backgrounds, thus providing a 
new avenue for the use of GEMMs as a preclinical model (Varticovski et al. 2007). 
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Owing to the diversity of human breast cancer and species differences, individual 
GEMMs should not be expected to faithfully recapitulate all aspects of the human disease 
but it is evident from the literature that over the past three decades, GEMMs have become 
invaluable tools for the investigation of human breast cancer genetics and pathogenesis, and 
that novel methods towards the optimization of their utility as preclinical models are still 
emerging.  
 
PI3K/AKT PATHWAY AND PTEN 
The phosphoinositide triphosphate kinase (PI3K)/AKT/mammalian target of 
rapamycin (mTOR) pathway is a central intracellular regulatory pathway, which is one of 
the most frequently activated signaling pathways in cancer. Phosphoinositide 3-kinases 
(PI3Ks) act by phosphorylating phosphatidylinositol lipid substrates, which in turn activate 
multiple effector proteins, and govern many cellular processes such as cell cycle 
progression, growth, differentiation, metabolism, survival and migration (Cantley 2002). 
Oncogenic mutations in the PI3K signaling pathway are frequently found in human cancers, 
including breast (Baselga 2011). These mutations generally involve either activating 
mutations in the genes encoding the kinases PIK3CA or AKT1, or the loss or reduced 
expression of the phosphatases PTEN, SHIP or INPP4B (Stemke-Hale et al. 2008). PIK3CA is 
found mutated in approximately 25-40% of all breast tumors (Cancer Genome Atlas 
Network 2012) and it has been suggested that PIK3CA mutations are an early even in breast 
cancer, more likely to play a role in breast cancer initiation than in invasive progression 
(Miron et al. 2010).  
While HER2 and ER! have been the most commonly used targets for the treatment 
of breast cancer patients, activated PI3K pathway is emerging as a major target for selective 
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therapeutics agents (Stemke-Hale et al. 2008). A diverse set of pharmacological inhibitors 
has been developed to inactivate this pathway in cancer cells (Courtney et al. 2010). 
However, trials thus far have demonstrated that monotherapy with a single targeted 
inhibitor is not capable of effectively eradicating the disease (Baselga 2011). For finding 
effective combination therapies that can counteract the inevitable resistance mechanisms 
being seen against these inhibitors, physiological preclinical mouse models that can 
accurately predict response to treatment are essential (Klarenbeek et al. 2013). 
The tumor suppressor gene PTEN is a negative regulator of the PI3K/Akt signaling 
pathway and is also found disrupted in many cancers (Cantley and Neel 1999). In fact, it is 
one of the most commonly lost or mutated tumor suppressor genes in human cancers (Song 
et al. 2012). Additionally, germ line mutations are found in several familial cancer 
predisposition syndromes (Liaw et al. 1997; Yin and Shen 2008). PTEN was initially 
identified as a gene frequently lost in brain, breast and prostate cancers (Li et al. 1997; Steck 
et al. 1997). Shortly thereafter, it was biochemically demonstrated that PTEN is a 
phosphatase responsible for the dephosphorylation of the messenger molecule 
phosphatidylinositol-3,4,5-triphosphate (Maehama and Dixon 1998) and that it was a 
negative regulator of the cell survival kinase Akt (Stambolic et al. 1998). In addition to its 
canonical role as a tumor suppressor gene in the PI3K pathway, in the context of breast 
cancer PTEN has been implicated in the resistance of HER2-targeted treatment (Nagata et al. 
2004; Berns et al. 2007) and has been shown to have a possible microenvironmental role in 
tumor-stroma co-evolution (Wallace et al. 2011). PTEN has been demonstrated to be acutely 
dose dependent in determining cancer susceptibility, defining it as a happloinsufficient 
tumor suppressor gene (Alimonti et al. 2010; Berger and Pandolfi 2011).  
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RNA INTERFERENCE AND SHRNAS 
In 1993, a new class of RNA molecules, later named microRNAs, was identified (Lee 
et al. 1993; Wightman et al. 1993). Through the discovery of RNA interference – a sequence-
specific gene silencing mechanism mediated by double-stranded RNA – a new era of loss-
of-function experimentation emerged (Fire et al. 1998), where it was possible, in principle, to 
reversibly suppress the expression of any gene in the genome. Although this mechanism of 
post-transcriptional gene silencing was first discovered in the nematode Caenorhabditis 
elegans, subsequent genetic and biochemical studies have revealed insights into the pathway 
and uncovered analogous mechanisms in eukaryotic organisms (Hannon 2002).  
MicroRNAs form the largest class of small non-coding RNAs and are involved in the 
spatio-temporal control of endogenous gene activity. This mechanism of negative regulation 
of target gene expression at the post-transcriptional level can be hijacked by double-
stranded RNA of exogenous sources to silence genes of interest in a sequence-specific 
manner. While transient regulation can be triggered in cultured mammalian cells through 
the introduction of synthetic siRNA duplexes (Elbashir et al. 2001), the use of viral vectors as 
a delivery vehicle for the stable expression of stem-loop structures resembling pre-miRNAs 
creates a renewable source of silencing reagents that can be transduced into almost any 
immortalized or primary cell type at controlled copy numbers (Brummelkamp et al. 2002; 
Paddison et al. 2002). 
By embedding an artificial hairpin-like structure into the physiological backbone of 
an endogenous miRNA (human miR-30), short hairpin RNAs (shRNAs) have been 
engineered to be recognized as a natural substrate. The hybrid pri-mRNAs expression 
cassette, which retains all the cis-acting sequences required for pri-miRNA processing, are 
processed through the canonical RNAi pathway and consequently allow for target 
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inhibition through the production of synthetic mature small RNAs (Silva et al. 2005). 
Further spatio-temporal control has been incorporated through the use of the RNA 
polymerase II-dependent promoter (Dickins et al. 2005; Stegmeier et al. 2005). Moreover, 
combining shRNA knockdown with tetracycline-regulated expression systems (Gossen and 
Bujard 1992; Gossen et al. 1995), as well as the use of fluorescent reporters, has conferred 
additional versatility to the use of this tool for conditional gene expression in both in vitro 
and in vivo studies (Premsrirut et al. 2011; Zuber et al. 2011a). 
 
 !  
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II. An oncogenomics-based in vivo RNAi screen for novel tumor 
suppressors genes relevant to breast cancer  
 
INTRODUCTION  
All cancers are a consequence of alterations in the DNA of a once healthy cell 
(Greenman et al. 2007; Stratton et al. 2009). Forward genetic screens can be used to identify 
the key tumorigenic drivers within loci that show copy number variation in human patients 
(Zender et al. 2008). This approach is founded on the hypothesis that chromosomal regions 
lost in human cancers are enriched for TSGs. Genomic instability, that is a characteristic of 
tumorigenesis, leads to the deletion and amplification of chromosomal regions. Such copy 
number alterations constitute one of several types of genetic aberrations that manifest in a 
cancer genome including specific DNA sequence mutations, structural rearrangements 
(translocations) and alterations in epigenetic profiles (Chin and Gray 2008). It can be 
postulated that deletion of regions enriched for TSGs will confer a proliferative and/or 
survival advantage to a cell and thus will be selectively maintained during tumor evolution 
(Bignell et al. 2010). In this manner, identifying recurrent alterations of the cancer genome 
can lead us towards a focused search for novel cancer genes (Velculescu 2008). 
Significant advances in sequencing technology over the past decade have allowed 
for an exponential increase in the resolution at which cancer cells can be analyzed (Futreal et 
al. 2001; Wood et al. 2007; Mardis 2008; McLendon R et al. 2008). The first fully sequenced 
cancer genome of a cytogenetically normal acute myeloid leukemia was published in 2008 
(Ley et al. 2008). The genomes and transcriptomes of the primary and metastasized lesions 
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of an estraogen-receptor-!-positive metastatic lobular breast cancer have also been 
sequenced at depth (Shah et al. 2009). 
A major challenge lies in translating such a vast catalogue of genomic information 
into clinical use (Chin and Gray 2008). Due to spontaneous mutagenesis, inherent 
chromosomal and genomic instability of cancerous cells, and association through genetic 
linkage, all genomic alterations displayed in cancers are not necessarily relevant to the 
progression of the disease itself (Zender et al. 2008). Previous studies by the Lowe 
laboratory have demonstrated that in vivo RNAi screening approaches allow for the efficient 
filtering of oncogenomic data and the identification of novel TSGs (Zender et al. 2008; Bric et 
al. 2009; Scuoppo et al. 2012). A similar methodology has also been applied towards the 
identification of oncogenes among frequently amplified regions of the genome (Sawey et al. 
2011).  
In order to perform an in vivo RNAi screen for TSGs relevant to breast cancer, we 
sought to develop an orthotopic transplantation model. Although constructing a high-
throughput platform proved challenging, a small gene-by-gene screen was conducted and 
Nf1, a gene that encodes neurofibromin 1 (NF1), was identified and validated in our mouse 
model as a putative TSG in HER2-driven breast cancer. Transgenic strains with shRNAs 
targeting Nf1 were subsequently generated for further studies. 
 
RESULTS 
Generating a list of candidate tumor suppressor genes and an shRNA library 
Regions of copy number variation can be identified using high-resolution array-
based comparative genomic hybridization (CGH). In collaboration with Jim Hicks and 
Michael Wigler at Cold Spring Harbor Laboratory (CSHL), a candidate TSG list was 
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generated from the analysis of genomic deletion and amplification frequencies of 247 
primary breast cancers and 43 breast cancer cell lines using representational oligonucleotide 
microarray analysis (ROMA) (Lucito et al. 2003; Hicks et al. 2006; Zender et al. 2008). 
In an effort to selectively identify recurrently deleted genes from the array data, 
criteria were established requiring deletions to represent focally deleted chromosomal 
regions of less than 5Mb and a minimum frequency of at least 5% within the overall dataset. 
Focal deletions were in most cases less than 1Mb in length. With the aid of supporting 
evidence from the literature, the original list was further refined to a focused set of 144 
genes [Table 2.1]. Mouse orthologs were identified using the open source database BioMart 
(www.biomart.org) (Haider et al. 2009), reducing the list to 112 candidates. Thirty-seven 
additional genes were curated from a Genentech study of high-resolution CGH analysis of 
51 breast tumors to supplement this list (Haverty et al. 2008), resulting in a total of 149 
candidate genes. Unfortunately, the ROMA breast cancer dataset was too small to segregate 
the patient samples by their molecular annotation without losing statistical significance, 
preventing us from compiling a list of candidate TSGs specific to the HER2 overexpression 
clinical subtype. However, later in this chapter, attempts to screen these candidate genes in 
a model of HER2-positive breast cancer will be discussed at length. In future iterations of 
RNAi screens seeking to identify cancer genes and drug targets relevant to human breast 
cancer, it will be critical to integrate the molecular profiles of clinical samples into the 
fundamental design of the project. 
The neural network siRNA algorithm BIOPREDsi developed by Novartis 
(http://www.biopredsi.org/) was used to design five unique shRNA sequences targeting 
the mouse ortholog of each candidate gene (745 shRNAs total) (Huesken et al. 2005) [Table 
2.2]. We have previously shown that stable suppression of gene expression can be achieved 
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Table 2.1  ROMA recurrent deletion tumor suppressor candidates  
 
Chromosomal regions Gene names 
chr5:16,723,108-17,775,055 MYO10 
 BASP1 
chr8:11,108,957-14,105,148 MTMR9 
 AMAC1L2 
 BLK 
 GATA4 
 NEIL2 
 FDFT1 
 CTSB 
 DUB3 
 DLC1 
 SGCZ 
chr8:34,256,633-36,524,467 UNC5D 
chr8:39,328,853-41,933,548 ADAM18 
 ADAM2 
 INDO 
 INDOL1 
 C8orf4 
 ZMAT4 
 SFRP1 
 GOLGA7 
 GINS4 
 AGPAT6 
 NKS6-3 
 ANK1 
 has-mir-486 
 MYST3 
chr9:37,004,824-38,655,208 PAX5 
 ZCCHC7 
 GRHPR 
 ZBTB5 
 PAF53 
 C9orf105 
 EXOSC3 
 WDR32 
 MCART1 
 ALDH1B1 
 IGFBPL1 
 ANKRD18A 
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chr9:78,799,360-83,235,988 TLE4 
 RASEF 
chr10:69,209,947-70,876,569 DNJC12 
 SIRT1 
 HERC4 
 FLJ14437 
 ATOH7 
 MAWBP 
 HNRPH3 
 RUFY2 
 SLC25A16 
 CXXC6 
 CCAR1 
 STOX1 
 DDX50 
 DDX21 
 PRG1 
 VPS26 
 SUPV3L1 
 HKDC1 
 HK1 
 TACR2 
chr11:46,327,487-48,083,630 DGKZ 
 MDK 
 CHRM4 
 AMBRA1 
 ARHGAP1 
 ZNF408 
 F2 
 CKAP5 
 LRP4 
 ARFGAP2 
 PACSIN3 
 DDB2 
 ACP2 
 NR1H3 
 MADD 
 MYBPC3 
 SPI1 
 SLC39A13 
 PSMC3 
 RAPSN 
 CUGBP1 
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 PTPMT1 
 KBTBD4 
 MTCH2 
 AGBL2 
 FNBP4 
 NUP160 
 PTPRJ 
chr11:56,305,352-57,532,499 OR5AK2 
 AGTRL1 
 TMLS1BP1 
 SSRP1 
 P2RX 
 SLC43A3 
 RTN4RL2 
 UBE2L6 
 SERPING1 
 YPEL 
 CLP1 
 HEAB 
 ZDHHC5 
 has-mir-130a 
 MED19 
 CTNND1 
chr11:71,383,633-71,895,665 RNF121 
 IL18BP 
 NUMA1 
 LRRC51 
 FOLR3 
 FOLR1 
 FOLR2 
 INPPL1 
 PHOX2A 
 SKD3 
chr11:73,675,366-74,237,477 P4HA3 
 PGM2L1 
 KCNE3 
 POLD3 
 CHRDL2 
chr11:83,312,841-84,692,488 DLG2 
chr13:19,212,114-20,340,806 PSPC1 
 ZNF237 
 ZNF198 
 GJA3 
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 GJB2 
 GJB6 
 TTC10 
 IL17D 
 LOC221143 
 XPO4 
chr17:26,402,098-28,056,700 NF1 
 OMG 
 EVI2A 
 EVI2B 
 RAB11FIP4 
 hsa-mir-193A 
 hsa-mir-365-2 
 C17orf40 
 RHOT1 
 RHBDL4 
 ZNF207 
 PSMD11 
 CDK5R1 
 MYO1D 
Genentech (Haverty et al.) candidates NOX3 
 TIAM2 
 CLDN20 
 ANGPT2 
 MFHAS1 
 PPP1R3B 
 hsa-mir-124a-1 
 RP1L1 
 SOX7 
 PINX1 
 XKR6 
 LONRF1 
 DLC1 
 GATA4 
 NEIL2 
 FGF20 
 EGR3 
 TNFRSF10A 
 EFHA2 
 PTK2B 
 hsa-mir-383 
 MAML2 
 MMP1 
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 CASP4 
 CASP5 
 COP1 
 CHEK1 
 hsa-let-7a-2 
 SMAD9 
 POSTN 
 CCNA1 
 RB1 
 hsa-mir-16-1 
 hsa-mir-15a 
 PCDH9 
 SQSE29775 
 EDNRB 
 SCEL 
 CHES1 
 STX8 
 RCV1 
 GAS7 
 MYH1 
 MAP2K4 
 MYOCD 
 ZNF18 
 LOC91353 
 LRP5L 
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Table 2.2  Candidate tumor suppressor gene shRNA library – 149 genes/745 shRNAs 
Acp2.1364 Ank1.153 Cdk5r1.1759 Ctsb.1897 Egr3.118 
Acp2.1824 Ank1.2400 Cdk5r1.1993 Ctsb.2102 Egr3.182 
Acp2.191 Ank1.2613 Cdk5r1.3373 Ctsb.215 Egr3.235 
Acp2.933 Ank1.4409 Cdk5r1.4051 Ctsb.3129 Egr3.38 
Acp2.95 Ank1.923 Cdk5r1.545 Ctsb.3229 Egr3.538 
Adam18.1508 ArfGAP2.1212 Chek1.1720 Cugbp1.1414 Evi2a.1073 
Adam18.1630 ArfGAP2.1892 Chek1.2012 Cugbp1.1755 Evi2a.723 
Adam18.334 ArfGAP2.2677 Chek1.2128 Cugbp1.1790 Evi2a.845 
Adam18.456 ArfGAP2.2688 Chek1.2348 Cugbp1.206 Evi2a.896 
Adam18.492 ArfGAP2.323 Chek1.729 Cugbp1.329 Evi2a.960 
Adam2.160 Arhgap1.2092 Chrdl2.1172 Ddb2.1336 Evi2b.1040 
Adam2.2398 Arhgap1.2352 Chrdl2.1313 Ddb2.364 Evi2b.2989 
Adam2.323 Arhgap1.3018 Chrdl2.1388 Ddb2.736 Evi2b.375 
Adam2.394 Arhgap1.381 Chrdl2.824 Ddb2.946 Evi2b.821 
Adam2.490 Arhgap1.896 Chrdl2.836 Ddb2.971 Evi2b.84 
Agbl2.1512 Atoh7.235 Chrm4.1208 Ddx21.1441 Exosc3.329 
Agbl2.2907 Atoh7.272 Chrm4.1484 Ddx21.1487 Exosc3.374 
Agbl2.3337 Atoh7.278 Chrm4.2267 Ddx21.395 Exosc3.620 
Agbl2.3368 Atoh7.373 Chrm4.2706 Ddx21.4037 Exosc3.715 
Agbl2.650 Atoh7.387 Chrm4.431 Ddx21.4419 Exosc3.980 
Agpat6.1823 Basp1.136 Ckap5.2579 Ddx50.1347 F2.1531 
Agpat6.2187 Basp1.495 Ckap5.3361 Ddx50.1476 F2.1630 
Agpat6.2465 Basp1.655 Ckap5.3671 Ddx50.1637 F2.1685 
Agpat6.476 Basp1.661 Ckap5.3923 Ddx50.2437 F2.1820 
Agpat6.711 Basp1.662 Ckap5.6478 Ddx50.2468 F2.1850 
Agtrl1.1869 Blk.1785 Cldn20.381 Dgkz.1156 Fdft1.1009 
Agtrl1.1960 Blk.2172 Cldn20.418 Dgkz.1166 Fdft1.1861 
Agtrl1.1968 Blk.385 Cldn20.443 Dgkz.2104 Fdft1.782 
Agtrl1.2532 Blk.625 Cldn20.634 Dgkz.3338 Fdft1.932 
Agtrl1.3374 Blk.94 Cldn20.641 Dgkz.3491 Fdft1.997 
Aldh1b1.1927 Casp4.1126 Clp1.1006 Dlc1.1594 Fgf20.418 
Aldh1b1.2190 Casp4.1254 Clp1.1386 Dlc1.2161 Fgf20.448 
Aldh1b1.2247 Casp4.1277 Clp1.162 Dlc1.3806 Fgf20.512 
Aldh1b1.524 Casp4.402 Clp1.702 Dlc1.4074 Fgf20.595 
Aldh1b1.88 Casp4.733 Clp1.711 Dlc1.5485 Fgf20.602 
AMBRA1.3565 Ccar1.261 Clpb.1556 Dlg2.2184 Fnbp4.1674 
AMBRA1.3831 Ccar1.2906 Clpb.3761 Dlg2.249 Fnbp4.2253 
AMBRA1.533 Ccar1.645 Clpb.3946 Dlg2.4827 Fnbp4.3353 
AMBRA1.534 Ccar1.691 Clpb.4074 Dlg2.6459 Fnbp4.4464 
AMBRA1.599 Ccar1.713 Clpb.444 Dlg2.961 Fnbp4.4649 
Angpt2.1082 Ccna1.1058 Ctnnd1.110 Ednrb.1478 Folr1.1242 
Angpt2.1279 Ccna1.1214 Ctnnd1.2122 Ednrb.1720 Folr1.202 
Angpt2.1641 Ccna1.163 Ctnnd1.2260 Ednrb.1954 Folr1.65 
Angpt2.1662 Ccna1.376 Ctnnd1.3138 Ednrb.3631 Folr1.650 
Angpt2.806 Ccna1.923 Ctnnd1.900 Ednrb.3701 Folr1.92 
! 25 
Folr2.1075 Grhpr.468 Inppl1.945 Mdk.474 Myo10.7990 
Folr2.355 Grhpr.628 Inppl1.1072 Mdk.631 Myo10.956 
Folr2.52 Grhpr.771 Inppl1.1627 Mdk.639 Myo1d.1890 
Folr2.680 Herc4.2552 Inppl1.3469 Mdk.642 Myo1d.1939 
Folr2.740 Herc4.2657 Inppl1.4434 Med19.1091 Myo1d.2145 
FoxN3.1482 Herc4.3413 Inppl1.457 Med19.1097 Myo1d.4761 
FoxN3.2207 Herc4.3568 Kbtbd4.1039 Med19.1147 Myo1d.720 
FoxN3.2386 Herc4.574 Kbtbd4.2145 Med19.1328 Myocd.2874 
FoxN3.2514 Hk1.209 Kbtbd4.2232 Med19.1776 Myocd.3969 
FoxN3.708 Hk1.2369 Kbtbd4.2266 Mfhas1.2757 Myocd.4206 
Gas7.3443 Hk1.2537 Kbtbd4.2359 Mfhas1.3288 Myocd.4499 
Gas7.3501 Hk1.2599 Kcne3.571 Mfhas1.4081 Myocd.658 
Gas7.4460 Hk1.2630 Kcne3.840 Mfhas1.4869 Myst3.2590 
Gas7.4483 Hkdc1.1016 Kcne3.88 Mfhas1.4961 Myst3.3127 
Gas7.6555 Hkdc1.3367 Kcne3.894 Mmp13.1241 Myst3.3485 
Gata4.2478 Hkdc1.3425 Kcne3.981 Mmp13.1284 Myst3.4554 
Gata4.2882 Hkdc1.3426 LONRF1.1065 Mmp13.1662 Myst3.6844 
Gata4.2989 Hkdc1.359 LONRF1.1533 Mmp13.1906 Neil2.1184 
Gata4.343 Hnrph3.1561 LONRF1.2779 Mmp13.2534 Neil2.1850 
Gata4.416 Hnrph3.1599 LONRF1.2852 Mtch2.1392 Neil2.440 
Gins4.1105 Hnrph3.1684 LONRF1.3622 Mtch2.2058 Neil2.787 
Gins4.1294 Hnrph3.1899 Lrp4.4384 Mtch2.2245 Neil2.923 
Gins4.621 Hnrph3.486 Lrp4.604 Mtch2.409 Nf1.3226 
Gins4.723 Igfbpl1.1968 Lrp4.6063 Mtch2.850 Nf1.6052 
Gins4.822 Igfbpl1.504 Lrp4.7106 Mtmr9.1156 Nf1.6074 
Gja3.1067 Igfbpl1.560 Lrp4.7332 Mtmr9.1627 Nf1.9045 
Gja3.139 Igfbpl1.624 Madd.1519 Mtmr9.1653 Nf1.9930 
Gja3.1391 Igfbpl1.792 Madd.1688 Mtmr9.1837 Nox3.1135 
Gja3.809 Il17d.1054 Madd.2701 Mtmr9.995 Nox3.1514 
Gja3.968 Il17d.1173 Madd.3130 Mybpc3.1176 Nox3.1550 
Gjb2.1905 Il17d.379 Madd.4588 Mybpc3.1367 Nox3.30 
Gjb2.2099 Il17d.806 Maml2.208 Mybpc3.3497 Nox3.894 
Gjb2.2264 Il17d.920 Maml2.2143 Mybpc3.3608 Nr1h3.1739 
Gjb2.569 Il18bp.1004 Maml2.3352 Mybpc3.4122 Nr1h3.1845 
Gjb2.599 Il18bp.1134 Maml2.3492 Myh1.2060 Nr1h3.1853 
Gjb6.1082 Il18bp.1266 Maml2.92 Myh1.2590 Nr1h3.563 
Gjb6.1252 Il18bp.1368 Map2k4.218 Myh1.283 Nr1h3.788 
Gjb6.1382 Il18bp.857 Map2k4.3198 Myh1.4540 Numa1.1262 
Gjb6.775 Indo.1030 Map2k4.3242 Myh1.5641 Numa1.1391 
Gjb6.882 Indo.1053 Map2k4.3553 Myh2.1129 Numa1.4538 
Golga7.1249 Indo.1367 Map2k4.420 Myh2.221 Numa1.6275 
Golga7.1353 Indo.1368 Mcart1.1792 Myh2.2240 Numa1.7111 
Golga7.142 Indo.1381 Mcart1.2770 Myh2.23 Nup160.2099 
Golga7.146 Indol1.1567 Mcart1.3405 Myh2.3767 Nup160.255 
Golga7.1685 Indol1.2425 Mcart1.3560 Myo10.1124 Nup160.5392 
Grhpr.1009 Indol1.2564 Mcart1.3803 Myo10.1685 Nup160.5556 
Grhpr.361 Indol1.296 Mdk.227 Myo10.6841 Nup160.992 
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Omg.1201 Polr1e.2910 Rab11fip4.2924 Rtn4rl2.203 Slc43a3.2572 
Omg.1378 Polr1e.388 Rapsn.1568 Rtn4rl2.457 Slc43a3.868 
Omg.1700 Polr1e.999 Rapsn.442 Rtn4rl2.905 Smad9.1349 
Omg.368 Postn.1066 Rapsn.682 Rtn4rl2.967 Smad9.2944 
Omg.800 Postn.1649 Rapsn.871 Rufy2.156 Smad9.2965 
P4ha3.1187 Postn.2709 Rapsn.96 Rufy2.2013 Smad9.3054 
P4ha3.1382 Postn.2764 Rasef.1619 Rufy2.4145 Smad9.4358 
P4ha3.1587 Postn.848 Rasef.1733 Rufy2.870 Sox7.1012 
P4ha3.305 Ppp1r3b.2670 Rasef.2360 Rufy2.8828 Sox7.1623 
P4ha3.669 Ppp1r3b.2720 Rasef.3787 Scel.1412 Sox7.2541 
Pacsin3.1067 Ppp1r3b.2793 Rasef.982 Scel.2134 Sox7.3030 
Pacsin3.1329 Ppp1r3b.340 Rb1.2317 Scel.2294 Sox7.3201 
Pacsin3.1598 Ppp1r3b.3999 Rb1.3736 Scel.253 Srgn.202 
Pacsin3.1685 Psmc3.1232 Rb1.4191 Scel.2892 Srgn.411 
Pacsin3.740 Psmc3.1524 Rb1.508 Serping1.1194 Srgn.536 
Pax5.154 Psmc3.318 Rb1.901 Serping1.1674 Srgn.661 
Pax5.328 Psmc3.59 Rcvrn1.1005 Serping1.1772 Srgn.865 
Pax5.601 Psmc3.947 Rcvrn1.231 Serping1.291 Ssrp1.1022 
Pax5.852 Psmd11.1021 Rcvrn1.557 Serping1.998 Ssrp1.1100 
Pax5.914 Psmd11.1081 Rcvrn1.576 Sfrp1.1803 Ssrp1.329 
Pbld.1197 Psmd11.1122 Rcvrn1.838 Sfrp1.1887 Ssrp1.431 
Pbld.1333 Psmd11.1149 Rfwd2.1866 Sfrp1.1978 Ssrp1.702 
Pbld.1434 Psmd11.139 Rfwd2.2025 Sfrp1.3781 Stx8.1328 
Pbld.1530 Pspc1.1714 Rfwd2.3664 Sfrp1.3903 Stx8.2538 
Pbld.660 Pspc1.180 Rfwd2.3816 Sgcz.1008 Stx8.3979 
Pcdh9.1446 Pspc1.2288 Rfwd2.4896 Sgcz.2367 Stx8.3995 
Pcdh9.4411 Pspc1.880 Rhbdl3.1333 Sgcz.401 Stx8.93 
Pcdh9.5145 Pspc1.993 Rhbdl3.1692 Sgcz.909 Supv3l1.1295 
Pcdh9.5219 Ptk2b.1393 Rhbdl3.3158 Sgcz.950 Supv3l1.1425 
Pcdh9.623 Ptk2b.1460 Rhbdl3.3319 Sirt1.1708 Supv3l1.1936 
Pgm2l1.1544 Ptk2b.3282 Rhbdl3.3465 Sirt1.1779 Supv3l1.496 
Pgm2l1.2972 Ptk2b.3571 Rhot1.1737 Sirt1.1921 Supv3l1.532 
Pgm2l1.3051 Ptk2b.551 Rhot1.1869 Sirt1.2191 Tacr2.1357 
Pgm2l1.3250 Ptpmt1.1078 Rhot1.3285 Sirt1.688 Tacr2.1531 
Pgm2l1.7527 Ptpmt1.1080 Rhot1.334 Slc25a16.1575 Tacr2.1780 
Phox2a.1307 Ptpmt1.1140 Rhot1.4055 Slc25a16.2535 Tacr2.1816 
Phox2a.1316 Ptpmt1.1201 Rnf121.416 Slc25a16.2639 Tacr2.228 
Phox2a.1373 Ptpmt1.884 Rnf121.60 Slc25a16.3108 Tiam2.2834 
Phox2a.1415 Ptprj.4708 Rnf121.740 Slc25a16.322 Tiam2.3111 
Phox2a.543 Ptprj.5046 Rnf121.768 Slc39a13.1018 Tiam2.5046 
Pold3.1213 Ptprj.5347 Rnf121.791 Slc39a13.1544 Tiam2.5567 
Pold3.2223 Ptprj.538 Rp1l1.4559 Slc39a13.2027 Tiam2.5675 
Pold3.2668 Ptprj.7284 Rp1l1.5608 Slc39a13.2236 Tle4.1870 
Pold3.427 Rab11fip4.1840 Rp1l1.5895 Slc39a13.778 Tle4.286 
Pold3.641 Rab11fip4.2058 Rp1l1.6565 Slc43a3.1040 Tle4.3126 
Polr1e.1726 Rab11fip4.2291 Rp1l1.6697 Slc43a3.2221 Tle4.3521 
Polr1e.2529 Rab11fip4.290 Rtn4rl2.1030 Slc43a3.2483 Tle4.822 
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Ube2l6.1022 Zmat4.1785    
Ube2l6.192 Zmat4.1806    
Ube2l6.461 Zmat4.604    
Ube2l6.620     
Ube2l6.630     
Unc5d.1851     
Unc5d.2469     
Unc5d.2930     
Unc5d.2952     
Unc5d.3319     
Vps26a.138     
Vps26a.1860     
Vps26a.2089     
Vps26a.713     
Vps26a.732     
Wdr32.2157     
Wdr32.2235     
Wdr32.3030     
Wdr32.3807     
Wdr32.6353     
Xkr6.1012     
Xkr6.310     
Xkr6.379     
Xkr6.852     
Xkr6.886     
Xpo4.1196     
Xpo4.2016     
Xpo4.2146     
Xpo4.2658     
Xpo4.375     
Zbtb5.1220     
Zbtb5.1228     
Zbtb5.2090     
Zbtb5.3265     
Zbtb5.379     
Zcchc7.430     
Zcchc7.503     
Zcchc7.588     
Zcchc7.831     
Zcchc7.859     
Zdhhc5.135     
Zdhhc5.2488     
Zdhhc5.4273     
Zdhhc5.542     
Zdhhc5.85     
Zmat4.1079     
Zmat4.1166     
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in vivo by utilizing a murine stem cell virus (MSCV) based retroviral vector that expresses a 
human miR-30-based shRNA (Dickins et al. 2005). This pLMS (MLS) vector also contains a 
constitutively expressed green fluorescent protein (GFP) marker, used to identify 
transduced cells [FIGURE 2.1a]. As described further in Materials and Methods, shRNAs 
were generated from a pool of 97mer oligonucleotides and subcloned into pLMS. Sanger 
sequencing of individual bacterial clones following retransformation of the pLMS pools 
allowed identification of individual shRNAs. This enabled the assembly of a sequence 
validated library and access to shRNAs targeting individual genes for follow-up analysis. 
The positive selection in vivo screen design is based on two assumptions: a) shRNA-
mediated silencing can mimic the loss of TSGs; b) if reduced protein levels of a candidate 
TSG confers a growth or survival advantage, that shRNA will be selectively enriched during 
tumor growth. To identify enriched shRNAs the following work-flow is employed: 1) once a 
tumor has developed, genomic DNA is isolated and shRNAs contained in the retrovirus are 
cloned out using sequence specific primers to the human miR-30 backbone; 2) changes in 
shRNA representation are assessed by comparing abundance of each shRNA in the initial 
population to its presence in the resulting tumor; and 3) over-represented shRNAs indicate 
the possible identification of a novel TSG. To avoid results obtained through off-target 
effects, it is important that more than one shRNA against any particular gene scores in the 
assay. Short hairpin RNAs also need to show specific target knockdown by qRT-PCR or by 
Western blot if an antibody is available. All positive hits identified from the pooled 
screening approach must also be validated in vivo as single shRNAs. A caveat to this 
screening approach is that the lack of an effective shRNA will result in a false negative 
result where a valid candidate TSG will be missed due to insufficient knockdown. Efforts to 
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ameliorate shRNA design and efficacy has been an on-going area of research by other 
members of the laboratory (Fellmann et al. 2011).  
 
Screening platform development 
There are several important criteria for designing a well-adapted in vivo cancer 
model system for the purpose of conducting a positive selection screen. Firstly, it must be 
physiologically relevant to the human disease, reflecting both the genetics and 
histopathology of the cancer. Secondly, representation of the screening library should be 
maintained following transplantation of the cell population, taking into account ‘tumor 
seeding’ rates. Thirdly, a robust screening assay, in this case tumor development, which 
provides a clear window for detection of disease acceleration over baseline. In sum, each 
tissue and disease type present unique mouse modeling challenges that require careful 
consideration in order to maximize the utility of in vivo experimentation. 
One advantage of a ‘mosaic’ transplantation model, where transduced mouse cells 
are orthotopically transplanted into a wild type recipient mouse, is that a physiological 
disease microenvironment is faithfully maintained (Zender et al. 2008; Bric et al. 2009; Zuber 
et al. 2009; Zuber et al. 2011b). With the exception of inherited genetic mutations, most 
tumorigenic cells arise surrounded by healthy, normal stromal tissue. Mosaic models also 
allow for a great deal of flexibility for the modular introduction of transgenes and RNAi 
constructs, as well as fluorescent and bioluminescent reporters that allow for easy tracking 
of the developing tumor. Importantly, primary cells with defined genetic manipulations are 
genetically tractable in a manner in which xenograft models relying on human cancer cells 
lines are not.  
 31 
We sought to exploit the observation that the majority of murine mammary gland 
development occurs postnatally in a method that would combine the gland-reconstituting 
capacity of mammary stem/progenitor cells (MaSCs) with ex vivo genetic manipulation via 
viral transduction. Initial attempts to develop an orthotopic transplantation-based, modular 
and mosaic mouse model of breast cancer consisted of the following features and steps [also 
shown schematically in Figure 2.1b]. Beginning at three weeks of age, the endogenous 
mammary epithelium begins to develop into and populate the fat and connective tissue of 
the mammary gland, a process which is compete by ten weeks of age (Richert et al. 2000). 
Primary MaSCs would therefore be isolated from the mammary glands of adult donor 
female mice, approximately 8-12 weeks in age. The primary cells would be maintained in 
mammosphere in vitro culture to enrich for the stem/progenitor cells prior to introducing 
shRNA plasmids via lentiviral infection. Transduced cells would be implanted into the 
cleared fat pads of three-week-old syngeneic recipient animals. The clearing process 
removes the native stem cell population, allowing for the transplanted cells to reconstitute 
the mammary epithelium during puberty. Previous studies have shown that a single 
mammary stem cell transplanted into the developing gland of a prepubescent mouse is 
capable of reconstituting the entire gland (Shackleton et al. 2006; Stingl et al. 2006). Tumors 
would then develop in an immune-competent, wild type animal in the presence of the 
appropriate stromal and microenvironmental cues.  
Although the intended model was optimal for positive selection, as it allows for 
implanted cells to fully integrate into the native glandular and stromal architecture before 
oncogenic transformation, it proved too complex to scale to a high-throughput screening 
platform. Side-by-side comparisons demonstrated that in our hands one freeze-thaw 
process could greatly reduce the efficiency of reconstitution following orthotopic 
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implantation of MaSCs (data not shown). The low yield of MaSCs per donor mouse made it  
prohibitively labor-intensive to harvest sufficient quantities of cells to conduct well-
controlled experiments. While preserving as many of the original design elements as 
possible, we sought to find feasible alternatives.  
The multi-potent mammary progenitor cell line Comma-D was a strong candidate to 
replace the primary cells for in vivo RNAi screening (Medina et al. 1986). Comma-D cells are 
capable of reconstituting a functionally normal mammary gland when transplanted into a 
cleared fat pad of a recipient mouse. However, these cells begin to transform after 
approximately twenty passages in culture and have two well-defined mutations in TP53 – a 
substitution of tryptophan for cysteine at codon 138 and a deletion of the first 21 nucleotides 
at exon five – that have been suggested as the sources of genomic instability and 
susceptibility to neoplastic transformation in vitro (Jerry et al. 1994; Barcellos-Hoff and 
Ravani 2000). The lack of genetic tractability and the heterogeneity following passages in 
vitro caused dual concern for building a screening system, as genomic instability could 
cause a high rate of transformation in vitro and variation among the cells could compromise 
even shRNA library infection efficiency and representation. Diluting c-Myc overexpressing 
Comma-D cells into MaSCs to directly assess differences in the reconstituted gland 
morphology was used to test their mammary gland reconstitution capability. Twelve weeks 
after implantation, we observed that a higher percentage of Comma-D cells gave a more 
hyperplastic, branched ductal morphology [Figure 2.2]. In contrast, those glands with a 
predominantly MaSC population closely resembled endogenous control glands. The high 
rate of transformation raised the possibility that each reconstituted gland would contribute 
many initiating tumor cells and consequently confound the assay.  !  
!!
A
B
C
!"#$%&'()('*+,"-"&,'+%./+.+0"1' .%2340523.2."+3'6+,&5'7"./'8+6629:'1&554'23,'*2;84)'
"#$% &'()*+,-'% ./% )01)2-*)3,+4% 5),671% /.2%*-0-38% !"#$!% .9)2)012)55-38%:.**+6;% ')445% +,%
9+2-.75% <-47,-.35% -3,.% 1.174+,-.3% ./% =+&:5>% "?$% @)'.35,-,7,)<% *+**+2A% 84+3<5% B)2)%
(+29)5,)<% +112.0-*+,)4A% CD%B))E5% +/,)2% -*14+3,+,-.3% +3<% 5,+-3)<%B-,(% '+2*-3)% ,.% 2)9)+4%
<7',+4%5,27',72)5>%":$%;),+-4)<%9-)B%'.*1+2-38%)3<.8)3.75%'.3,2.4%*+**+2A%84+3<%,.%CFG%
<-47,-.3%./%:.**+6;%,.%=+&:5H%+%-3'2)+5)%-3%(A1)214+5,-'%I2+3'(-38%-5%9-5-I4)>%
Control gland 1:1 1:5 1:10 1:25
Comma-D : MaSC dilution
Control gland
Comma-D : MaSC
         1 : 5
 34 
NMuMG cells are non-transformed mouse mammary epithelial cells that were 
originally derived from normal glandular tissue of an adult NAMRU mouse (Owens 1974; 
David et al. 1981; Hall et al. 1982). They were the next choice for a mouse mammary 
epithelial cell line because at low-passage NMuMG cells have been demonstrated to have 
typical epithelial morphology, display no cytologic instability, and also form structurally 
normal continuous basal lamina in vivo when injected into athymic nude mice (David et al. 
1981). They have been used extensively in the literature to study transforming growth 
factor-beta (TGF-!) signaling and epithelial to mesenchymal transition (EMT) (Piek et al. 
1999; Deckers et al. 2006). One major disadvantage of the NMuMG cell line, however, is the 
discontinuation of its syngeneic NAMRU strain, whereas Comma-D cells can be re-injected 
into syngeneic BALB/c mice (Medina et al. 1986).  
There was no clear evidence in the literature to suggest that NMuMG cells had lost 
functional p53, an important step in tumorigenesis in many tumor types. Mutations in TP53 
occur at a frequency of ~23% in breast cancer, where is it the second most frequently 
mutation gene after PIK3CA (26%) (COSMIC) (Forbes et al. 2011). We reasoned that 
depletion of p53 in NMuMG cells might accelerate disease and serve as a clinically relevant 
positive control for the screen. To verify that NMuMG cells express functional p53, the 
parental cell line was treated with the DNA damaging agent Adriamycin that is known to 
promote stabilization of p53 and downstream activation of p21 (Watring et al. 1974). As 
expected Adriamycin treatment (0.25µg/mL) induced a dramatic upregulation of p53 and 
p21, an effect that was abrogated in the presence of a potent shRNA targeting p53 (shRNA-
p53.1244) (Dickins et al. 2005; Xue et al. 2007) [Figure 2.3]. We were unable to detect p19ARF 
by Western blot but could not rule out this may be due to technical difficulties with the 
antibody. Alternatively, gain of replicative potential in culture often comes as a consequence 
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of the loss of the INK4A/ARF locus (Collado et al. 2007), and this could be expected as a 
step in the immortalization process of this cell murine line cell. 
The first three elements in defining an RNAi screening platform are the sensitized 
background, shRNA pool size and positive controls. We considered the use of 
overexpressed c-Myc and HER2, as well as a mutant PI3 kinase catalytic subunit p110! 
(PIK3CAH1047R), as the sensitizing oncogenic stimulus. Ideally, since the candidate genes in 
our library were identified from patients comprising multiple different subtypes of breast 
cancer, the screen would be performed in multiple sensitized backgrounds in order to 
identify context specific as well as common TSGs. 
We began by lentivirally transducing NMuMG cells with a construct containing the 
mutant rat ortholog of ERBB2, neuV664E (NeuNT), driven under the control of the Ubiquitin C 
(UbC) promoter. Neu has been commonly used in transgenic mouse models of HER2-
positive breast cancer to mimic the effects of HER2 overexpression frequently seen in 
patients (Muller et al. 1988; Bouchard et al. 1989). Our data showed that overexpression of 
NeuV664E initiated tumor formation in NMuMG cells injected into the fat pads of nude mice 
[Figure 2.4], in contrast to parental NMuMG cells that do not form tumors at long latency 
(over 3 months post-injection; data not shown). 
We discovered that an shRNA targeting the TSG phosphatase and tensin homolog (Pten) 
was highly efficient in accelerating the disease onset and tumor size in NeuNT 
overexpressing NMuMG cells, even more strongly than shRNA-p53.1244 [Figure 2.5]. 
Further testing confirmed this result but also uncovered that the window for detection of 
disease acceleration between RNAi of a real positive control or candidate TSG and the 
appearance of baseline disease driven by the aggressive oncogenic stimulus was less than 
four weeks (data not shown). Factoring the inevitable variability of in vivo experimentation, 
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several weeks represented an insufficient period of time for conducting a positive selection 
screen of any complexity with the requisite sensitivity. However, pilot in vivo assays using 
GFP reporter tagged shRNA-Pten.1522 demonstrated a quantifiable success in increasing its 
representation within a tumor as compared to neutral shRNA controls (data not shown). We 
posited that decreasing the strength of the NeuNT cDNA overexpression might address this 
lack of dynamic range. Deriving clonal cell lines to standardize and quantify oncogene 
expression levels, reducing the multiplicity of infection (MOI) during lentiviral 
transduction, and using a weaker promoter were among several strategies we tested in an 
attempted to increase the temporal resolution of our orthotopic transplantation assay by 
delaying the onset of disease driven by the sensitizing driver alone.  
Our first attempt to address these issues involved replacing the bulk population of 
transduced cells that was potentially comprised of diverse oncogene expression levels and 
cellular phenotypes. By deriving clonal lines we were able to cross-compare NeuNT 
expression levels, observe growth rates in vitro and verify for cobblestone epithelial 
morphology indistinguishable from the parental population [Figure 2.6a]. Two sub-clonal 
lines with moderate oncogene expression, compact epithelial cellular morphology and 
moderate growth rates – NMuMG UbC-NeuNT Clone #6 and #7 – were expanded and 
tested in vivo along side the parental bulk-population [Figure 2.6b-c]. In both bulk 
populations and clonal lines, shRNA-Pten.1522 showed reproducible acceleration of tumor 
formation compared to a neutral control shRNA that targets Renilla Luciferase (RLuc.713). 
Ultimately, however, the latency of tumor onset and tumor growth rates were still too 
aggressive to envisage a positive selection screen, as assessed by the failure to observe 
enrichment of a potent shRNA targeting an established TSG such as Pten when introduced 
into cells with a 50-fold excess of a neutral shRNA construct [Figure 2.6d].  
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Several promoters tagged with GFP were tested for expression levels in NMuMG 
cells in an attempt to identify a weaker substitute for the UbC promoter (data not shown). A 
suitable replacement was not found but we were reassured to find that the Cytokeratin-19 
(CK-19) promoter expressed well in these cells, confirming their luminal cellular origins.  
In a further attempt to reduce the aggressiveness of the spontaneous disease, a wild 
type sub-clonal line of NMuMG cells dubbed “NMEC#6” (NMuMG Mammary Epithelial 
Cells Clone #6) was transduced with lower titers of UbC-NeuNT lentivirus to decrease the 
number of viral integrations and clones were isolated following antibiotic selection. Low-
expressing NeuNT clones were identified by ‘In-Cell’ Western blot for ErbB2/neu 
expression [Figure 2.7a]. Since empirical observations from in vitro work with the parental 
NMuMG cells indicated heterogeneity in cellular morphology, several NMEC clonal lines 
were produced and tested (data not shown). NMEC#6 had tight epithelial cell-to-cell 
junctions, cobblestone cellular morphology, a moderate growth rate in vitro, and 
importantly, maintained these traits for many passages in culture. The NMEC#6 clone was 
also tested in vivo and like the untransformed parental line did not give rise to tumors at 
long latency (data not shown).   
NMEC#6 UbC-NeuNT clonal line #3 and #5 were tested in vivo with control 
shRNAs undiluted and in 1:50 dilution configurations, employing a combination of both 
GFP and dsRed flurescent marker-tagged vectors [Figure 2.7b: results shown only for clonal 
line #5]. The populations transduced with GFP tagged shRNA retrovirus were 
approximately 30% for undiluted controls and approximately 1% for 1:50 dilutions [Figure 
2.7c]. Tumors were harvested 7.5 weeks after orthotopic injection and gross anatomy was 
observed using a dissecting microscope to assess levels of the fluorescent reporters [Figure 
2.7d]. In tumors resulting from cells co-expressing shRNA-Pten.1522 were significantly 
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larger than control tumors and there was a net increase in the GFP signal, confirming that 
we were able to detect the oncogenic contribution of a strong TSG shRNA over baseline in 
these cells [Figure 2.7e]. Similar assays were used to investigate the potential utility of c-
Myc, mutant PIK3CA, human HER2, wild type mouse ErbB2 and activated mutant 
ErbB2(NT) as sensitizing lesions. However, these experiments all yielded inconsistent 
results in vivo (data not shown) and ultimately we chose to concentrate our efforts on 
optimizing NeuNT in our screening platform development.   
Before embarking on a screen for all 745 shRNAs in our library, we decided to first 
test whether shRNA-Pten.1522 TSG activity could be successfully identified from a pool of 
non-neutral shRNAs. A random pool of 49 sequence-verified shRNAs from the library were 
assembled and spiked with either the Pten.1522 or RLuc.713 control shRNA and tested in 
the same in vivo assay as before with NMEC#6 UbC-NeuNT clonal line #5. The pMLS 
plasmid pools were transduced at low MOI that approximated a single retroviral integration 
per cell. Disappointingly, shRNA-Pten.1522 failed to enrich in this context (data not shown), 
and the decision was made that the system established was not suitable for large pooled-
format screening. Instead efforts were focused towards testing a small set of candidates on a 
gene-by-gene basis. 
 
Pilot screen 
For the gene-by-gene trial, fourteen candidates were chosen from a list of 35 genes 
that represented an overlap between two methods of ROMA data analysis [Table 2.3]. The 
initial analysis had been founded on focal event counting, where the frequency and size of 
the chromosomal deletions detected in the CGH arrays produced a candidate list of 144 
genes (of which 112 incorporated into the shRNA library). The Genentech study had been 
! 44 
Table 2.3  Candidate tumor suppressor genes screened in gene-by-gene pilot 
Candidate Gene name a. b. c. pilot screen 
ARHGAP1 Rho GTPase activating protein 1 
 
x x x set 1 
BASP1 brain abundant, membrane 
attached signal protein 1 
x x x set 1 
Ctnnd1 catenin (cadherin-associated 
protein), delta 1 
x x  set 2 
CUGBP1 CUG triplet repeat, RNA binding 
protein 1 
x  x set 2 
DLG2 discs, large homolog 2 (Drosophila) 
 
x x x set 1 
FNBP4 formin binding protein 4 
 
x  x set 1 
KBTBD4 kelch repeat and BTB (POZ) 
domain containing 4 
x  x set 2 
MAP2K4 mitogen-activated protein kinase 
kinase 4 
x  x set 1 
MYO10 myosin X 
 
x x x set 2 
Nf1 neurofibromin 1 
 
x x  set 2 
Numa1 nuclear mitotic apparatus protein 1 
 
x x  set 2 
PTPRJ protein tyrosine phosphatase, 
receptor type, J 
x  x set 1 
UNC5D uncp5 homolog D (C. elegans) 
 
x x x set 2 
ZCCHC7 zinc finger, CCHC domain 
containing 7 
x  x set 1 
 
a. 5% focal deletion analysis (149 gene library) 
b. high potential "priority" candidates (19 genes) 
c. pinning algorithm candidates (500 genes) 
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used to complement that list with another 37 genes derived a list of 49 candidates. 
Additionally, during the process of the original library design 18 candidates had been 
flagged as ‘high priority’ based on information regarding the candidate in the literature, 
such as their involvement in particular pathways or as TSGs in other cancer types. These 
lists were compared to new set of 500 candidate genes generated by a second analysis 
method applied to the same ROMA datasets by Alex Krasnitz (CSHL) using a ‘pinning 
algorithm’.  
One of the more commonly applied methods of CGH profile analysis is by event 
counting, where a frequency plot of all loci in the sample data set is produced to visualize 
this basic measure of recurrence of copy number gains and losses. In many cancer types 
including breast, large chromosomal events are common and such simplistic methods of 
assessing relevance through frequency can lead to large portions of the genome being 
flagged. The ‘pinning algorithm’ was an alternative method of data analysis developed by 
Alex Krasnitz to allow for a more focused search for candidate driver genes where the 
length of any copy number variation and the potential for the overlapping events to move 
the calculated peak away from the actual epicenter is also taken into account. Surprisingly 
only 42 genes overlapped between the two candidate lists (38 with ROMA and 4 with 
Genentech candidates), 35 of which were part of our shRNA library, underscoring the 
importance in the choice of methods for the data analysis, both conceptually and 
computationally.  
We combined the shRNA plasmids for transfection into a packaging cell line, 
generating small pools of five sequence-verified shRNAs targeting each gene. Knockdown 
efficiency of the shRNAs against each target was not tested prior to the assay. Each small 
pool was introduced into NMEC#6 UbC-NeuNT (clonal line #5) using a viral titer intended 
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to generate cell populations carrying multiple viral integrations, thus increasing the 
likelihood of potent gene silencing. Infection rates were determined by assessing percentage 
of GFP positive cells: for the first set an average of 83.4% GFP positivity (range 73-89%) and 
for the second set an average of 77.8% (range 72-87%). For practical reasons we conducted 
the ex vivo manipulations and orthotopic injection surgeries in two batches, each round with 
its own set of controls. All experimental steps were conducted in identical manner. Tumors 
were harvested 7 and 8.5 weeks post-transplantation for the first and second sets, 
respectively. None of the candidate gene shRNA pools gave statistically significant results 
[Figure 2.8]. In some cases there seemed to be a no selective advantage afforded by the 
shRNA pool in this assay since GFP negative tumors were also observed (data not shown). 
The screen was repeated in NMEC#6 cells expressing CMV promoter driven wild type 
mouse ErbB2 but this experiment similarly produced no positive selection of candidate gene 
pools. The overall latency was very long and we also experienced incomplete penetrance of 
the positive control (data not shown). 
We noticed that despite a lack of statistical significance in tumor weight at harvest, 
the tumors resulting from the shRNA pool targeting the gene neurofibromin 1 (Nf1) did 
present an above average tumor burden and importantly, all four tumors were GFP 
positive. Encouraged by these results, the Nf1 shRNA pool was retested. Tumors were 
harvested and weighed two months post-transplantation and this time the increase in tumor 
burden was statistically significant [Figure 2.9a,b]. Crude tumor lysates were probed for 
NF1 protein levels and strong knockdown was observed [Figure 2.9c], but there were no 
major changes in histology, density of GFP positive cells or growth as indexed by Ki-67 
staining [Figure 2.9d,e]. We verified protein knockdown efficacy of each shRNA 
individually at both high and low MOI levels in NMuMG cells [Figure 2.10a]. Owing to 
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technical difficulties regarding the health of nude mice under experimentation we were 
unable to draw any robust conclusions, but accelerated tumor onset and growth was also 
documented in the context of PIK3CAH1047R (with 5 shRNA pool) and wild type mouse 
ErbB2 overexpression (with two independent shRNAs alone) in NMEC#6 in vivo 
transplantation assays, albeit at a longer latency of approximately 5 months (data not 
shown).  
NF1 is an established TSG in leukemia and is well characterized as a negative 
regulator of the oncogene Ras (Mullally and Ebert 2010). As a Ras-GTPase activating protein 
(GAP), its loss can lead to the constitutive activation of the Ras pathway in a manner similar 
to oncogenic point mutations in Ras itself (Kalra et al. 1994; Bollag et al. 1996). We 
investigated the Nf1 pool shRNA tumor lysates for changes in the downstream signaling 
and found an upregulation in phosphorylated ERK, phosphorylated MEK, and 
phosphorylation of AKT at both the Thr-308 and Ser-473 sites [Figure 2.10b]. Unexpectedly, 
we did not perceive any of these changes in cells transduced with Nf1 shRNAs growing in 
vitro, and similarly we also did not observe any changes in growth or cellular morphology 
in culture. We attributed the lack of changes in signaling to the growth factor rich culture 
conditions that included insulin and 10% fetal bovine serum.  
In an attempt to identify differences in signaling in NMuMG cells transduced with a 
functionally validated and potent shRNA targeting Nf1, the effects of growth factor 
stimulation time course with epidermal growth factor (EGF) and insulin after an overnight 
starvation (no serum or insulin) were investigated. Neither in the presence or absence of 
NeuNT did we observe any changes in signaling [Figure 2.11]. Since it is conceivable that 
NF1 loss would result not in a strong signal upon upstream stimulation but instead allow 
for a prolongation of any signal downstream of Ras, we next performed a time course where 
!"
A
B
!"#$%&'()*+',-."/".$01'2!*'34526'7-897.8:-'1&/&13'0-.'.8:-3;%&0<'3"#-01"-#'940-#&3'
"-'2!*'7-897.8:-'.%"/&-';$<8%)'#$%&'()*(+,&-./*)&0))())1,2&345&6,/768/9,&1,&3:;<=>&
7(..)&+(*+/?1+0..@&1,4(7*(8&:ABC)DE3$)&0,8&FG+/H@71,&)(.(7*(8I&#J%&'()*(+,&-./*)&/,&F+/*(1,&
.@)0*(&4+/H&!"#$!%&'&7G.*G+(8&7(..)&0,8&*GH/+&.@)0*()K&-.G(&0,8&+(8&-/L(8&0+(0)&7/HF0+(&7/,*+/.&
*GH/+&91*D&()*# )DE3$& F//.& *GH/+& .@)0*(&91*D& D12D& F(+7(,*02(& /4& MNB& (LF+())1,2& 7(..)K&
1,7+(0)(8&)12,0.&1,&FD/)FD/C:(6O&FD/)FD/C;+6O&0,8&FD/)FD/C$6*&/-)(+?(8I
Low MOI infection High MOI infection
No
n-i
nf.
Luci.1309 (High MOI)
75
%
50
%
25
%
12
.5%
-Tubulin
-Nf1
-GFP
10
0%
Nf
1.3
22
6
Nf
1.6
07
4
Nf
1.8
59
4
Nf
1.9
04
5
Nf
1.9
93
0
No
n-i
nf.
Luci.1309 (High MOI)
75
%
50
%
25
%
12
.5%
10
0%
Nf
1.3
22
6
Nf
1.6
07
4
Nf
1.8
59
4
Nf
1.9
04
5
Nf
1.9
93
0
-Tubulin
-phospho Erk 1/2
-GFP
-Erk 1/2 total
-phospho Mek 1/2
-Mek-1 total
-Mek-2 total
-phospho Akt 473
-phospho Akt 308
-Akt total
-phospho S6
-S6 total
-S6K total
Selected high moi cell lines
(no oncogene)
Tumor lysates
NMEC#6 UbC-NeuNT clone #5 background
NM
EC
#6
 M
LP
-Lu
cif
era
se.
13
09
NM
EC
#6
 M
LP
-N
f1.
60
74
 
NM
EC
#6
 M
LP
-N
f1.
85
94
N6
-5 
ML
S-L
uc
ife
ras
e.1
30
9 (
Tu
mo
r #
3)
N6
-5 
Nf
1 M
LS
-5h
p p
oo
l (T
um
or 
#1
)
N6
-5 
Nf
1 M
LS
-5h
p p
oo
l (T
um
or 
#2
)
!"
!"#$%&' ()**' +"#,-.",#' /01,23%&-4' 05' 6!*' -53&%' #%0137' 5-830%' 23"4$.-3"0,' 3"4&' 80$%2&)#
$%&'%()#*+,'&#,)#-(,'%.)#+/&0'%&#,1#234567#8%++&#.)#89+'(9%#.)#':%#-(%&%)8%#,(#0*&%)8%#,1#0)#
&:;2<#'0(=%'.)=#!"#$0)>#?.+>'/-%#@,9&%#4(*AB#,C%(%D-(%&&.,)E
1. Growing
2. Starved overnight
3. Starved overnight, 10 min EGF/Insulin
4. Starved overnight, 30 min EGF/Insulin
5. Starved overnight, 1 hour EGF/Insulin
6. Starved overnight, 2 hours EGF/Insulin
7. Starved overnight, 3 hours EGF/Insulin
-Tubulin
-phospho Erk 1/2
-GFP
-Erk 1/2 total
-phospho Mek 1/2
-Mek-1 total
-Mek-2 total
-phospho Akt 473
-Akt total
-phospho S6
NMEC#6 NMEC#6 CMV-wildtype mouse ErbB2
MLP-Luciferase.1309 MLP-Nf1.8495 MLP-Luciferase.1309 MLP-Nf1.8495
1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7
faded bands: blotting error
 52 
cells were starved for 6 hours, stimulated with EGF/insulin for 10 minutes, then maintained 
in starvation conditions for a variable length of time. Once again, no significant changes 
were observed in downstream signaling phosphorylation by Western blot [Figure 2.12]. To 
generate a reagent that would allow us to study the tumor suppressive mechanism of NF1 
loss in vitro more effectively in the future, we established a series of tumor-derived cell lines 
from NMEC#6 transplant tumors expressing two MLP-shRNAs against NF1 (data not 
shown).  
The original CGH array data was re-examined to verify that NF1 deletions, found at 
a frequency of 5% in this small dataset, co-occur with ERBB2 chromosomal amplifications. 
There is some indication of linkage between focal deletions of NF1 (on 17q11.2) and ERBB2 
(on 17q12), which would imply a lack of biological significance in the co-occurrence of these 
events within tumors. The TSG TP53 is located on the short arm of chromosome 17 (17p13.1) 
and there also appears to be a frequent overlap between TP53 and NF1 deletions (over 10% 
in human breast cancer cell lines). When considering broader deletions encompassing NF1, 
they appear random with regard to MYC or ERBB2 amplification but are found to co-occur 
in both cases (Jim Hicks, personal communication).  
 
Making new shRNA transgenic mouse strains targeting Nf1 
As a parallel strategy for investigating the role of NF1 in breast cancer, we generated 
two tetracycline-inducible shRNA transgenic mice that enable reversible silencing of 
endogenous NF1 expression. To do this we took advantage of previous work by Lowe lab 
colleagues who established a fast and reproducible pipeline for the production of these 
shRNA transgenic strains (Premsrirut et al. 2011; Dow et al. 2012). A gene-targeting vector 
can be rapidly cloned to contain the shRNA sequence of choice in an inducible expression 
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cassette flanked by FRT sites. The shRNA cassette consists of the human miR-30-based 
shRNA embedded in the 3’ UTR of a GFP transcript downstream of a tetracycline 
responsive element (TRE) promoter [Figure 2.13a]. In our case, we employed a modified 
targeting construct containing the TREtight promoter (TREt), which shows 40-fold lower 
expression in the absence of tetracycline analog doxycycline (dox) compared to the 
conventional TRE promoter (Clontech 2003; Backman et al. 2004). This modification had 
been validated in transgenic models expressing shRNAs targeting essential genes where it 
had been imperative that basal expression levels be reduced (McJunkin et al. 2011).  
Following electroporation of the targeting vector alongside a plasmid expressing 
Flpe recombinase into KH2 ESCs, the TRE(t)-GFP-miR30 construct integrates into a defined 
locus downstream of the collagen A1 gene (ColA1) on mouse chromosome 11 via 
recombinase-mediated cassette exchange (Beard et al. 2006; Premsrirut et al. 2011) [Figure 
2.13a]. KH2 cells are 129, C57BL/6 F1 hybrid ESCs that contain not only the ColA1 homing 
cassette but also a reverse tetracycline-transactivator (rtTA) cDNA expressed from the 
endogenous Rosa26 promoter (Hochedlinger et al. 2005; Beard et al. 2006). In this ‘Tet-On’ 
system, the presence of dox can drive expression of the GFP-shRNA cassette in the targeted 
KH2 ESCs (Gossen et al. 1995).  
We generated targeted clones using three different NF1 shRNAs in KH2 ESCs and 
examined knockdown by western blot in two independent clones following 5 days 
treatment with dox. All three shRNAs showed robust protein knockdown [Figure 2.13b]. 
We decided to proceed with shRNA-NF1.6074 and NF1.8594 because these had previously 
been shown to be functionally active in accelerating disease in AML in vivo models. Three 
clones for each shRNA that showed compact, undifferentiated ESC morphology were 
placed on and off dox before assessment of GFP induction levels [Figure 2.13d]. Single-site 
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integration was also verified by Southern blot [Figure 2.13c]. Finally, candidate clone lysates 
were blotted once more to confirm protein knockdown levels [Figure 2.13e]. The clones 
displaying the strongest shRNA induction, protein knockdown, and healthiest 
undifferentiated ESC morphology were used for mouse production by tetraploid embryo 
complementation (Eggan et al. 2001). The production of transgenics by tetraploid 
complementation guarantees that recombined cells contribute to both somatic and germ line 
tissues in resultant male founders, permitting heritable transmission of transgenic alleles 
(KH2 cells are XY). 
 Once TtG-shNF1.6074 and TtG-shNF1.8594 founders reached sexual maturity they 
were crossed with C57BL/6 females in order to isolate mouse embryonic fibroblasts (MEFs) 
from embryos harboring both the Rosa26-rtTA-M2 (Rosa-rtTA) and TREt-GFP-miR30 alleles 
(Hochedlinger et al. 2005). Reversible GFP induction in the MEFs was verified by FACS 
analysis (data not shown). NF1 knockout strains are embryonic lethal when homozygous 
(Brannan et al. 1994). However, preliminary results from dox treated embryo litters did not 
show any phenotype in double transgenic pups, suggesting there was an insufficient 
knockdown of the target NF1 by either of the shRNAs tested in our model [Figure 2.14].  
As the expression pattern of TREtight-GFP-miR30 had not been previously 
examined in detail, we sought to test the induction of the allele in the presence of Rosa-rtTA 
in adult female mice after two weeks of dox treatment and also to compare the GFP 
induction levels in various tissues types between the TRE and TREtight promoters. 
Additionally, we included a different rtTA allele, CAGs-rtTA3, which has a broader and 
stronger expression pattern than the Rosa allele (Premsrirut et al. 2011). This data is 
summarized in the Appendix, and indicates a limited application of the TtG-shNF1.6074 
and TtG-shNF1.8594 transgenic strains for modeling NF1 loss more broadly, as neither short 
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hairpin will be capable of sufficient suppression of its target in many tissue types while in 
their current configuration downstream of the TREt promoter. 
The results for TREt promoter induction in the mammary gland were inconclusive. 
However, from previous work it had been established that TRE expresses robustly in the 
mammary gland when combined with CAGs-rtTA3 and MMTV-tTA (data now shown). We 
therefore intend to test TtG-shNF1.6074 and TtG-shNF1.8594 in the multi-allelic transgenic 
model described in Chapters 3 and 4. Preliminary evidence suggests that the TREt 
promoter, like TRE, can be induced in that model (data not shown) and experiments to 
validate NF1 as a tumor suppressor in this transgenic setting are currently ongoing.  
 
DISCUSSION 
This chapter describes efforts towards conducting a positive selection screen for the 
identification of novel tumor suppressors in breast cancer based on copy number variation 
data from human breast cancer genomic analysis. The approach was founded on the 
hypothesis that chromosomal regions frequently deleted in human cancers are enriched for 
TSGs. While some preliminary trials were conducted with c-Myc, mutant PIK3CA and wild 
type ErbB2 with mixed results, most of our efforts centered around the use of a mutant neu 
allele as the sensitized background for modeling HER2-positive breast cancer. In the context 
of developing an orthotopic transplantation model, we encountered considerable difficulty 
in establishing the appropriate level of oncogenic stimulus. Where the other oncogenes gave 
incomplete penetrance even at long latency, NeuNT was too aggressive and did not allow 
for a large enough window for the detection of accelerated disease over baseline. 
Although we were unsuccessful in developing a high throughput platform suitable 
for screening, we noticed that our strong positive control shRNA against Pten was capable 
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of undergoing positive selection in our in vivo orthotopic transplantation assay employing 
NMuMG cells. In an alternative gene-by-gene approach, we conducted a small pilot screen 
for high priority candidate TSGs frequently deleted in human breast tumor tissue, which 
lead to the identification of neurofibromin 1 (Nf1).  
When first identified in the pilot screen there was little evidence in the literature 
linking NF1 directly to breast cancer as a tumor suppressor gene, with the exception of one 
study demonstrating the failure of the human breast cancer cell line MDA-MB-231 to 
express NF1 (Ogata et al. 2001) and a few publications that addressed the increased risk of 
breast cancer in patients with the common autosomal dominant genetic disorder 
neurofibromatosis type I (NF-1) which is caused by inherited mutations in NF1 (Guran and 
Safali 2005; Sharif et al. 2007; Brems et al. 2009; Ripperger et al. 2009; Salemis et al. 2010). 
Only two reports implicated spontaneous NF1 loss to breast cancer tumorigenesis (Guran 
and Safali 2005; Lee et al. 2010). However, analysis of The Cancer Genome Atlas (TCGA) 
breast cancer data sets has revealed that 27.7% of human breast tumors have NF1 deletions 
or mutations, most being heterozygous (Wallace et al. 2012). Furthermore, in basal and 
HER2-positive patient subtypes as high as 40% of tumors display NF1 loss or mutation. In 
their study, Schimenti and colleagues examined the genomic profiles of tumors arising in 
inbred Chaos3 mice that exhibit high levels of genomic instability leading to mammary 
tumors and found that Nf1 was lost in 59 out of 60 tumors analyzed by CGH (Wallace et al. 
2012). An earlier study by Shannon and colleagues had found that mutagen-exposed 
(radiation and cyclophosphamide) heterozygous Nf1 mutant mice developed soft tissue 
sarcomas and breast carcinomas (Chao et al. 2005). Collectively, these studies support our 
preliminary finding that NF1 is a candidate tumor suppressor in breast cancer and provides 
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a possible explanation as to why Ras mutations are found so rarely in breast tumors (HRAS 
1%, KRAS 4%, NRAS 2%) (Pylayeva-Gupta et al. 2011). 
NF1 has been studied primarily as a tumor suppressor in myeloid malignancies but 
in addition to breast, but there is increasing evidence to suggest that it is also involved in 
solid cancers such as lung (Ding et al. 2008; De Raedt et al. 2011), colon (Cacev et al. 2005; 
Ahlquist et al. 2008), glioblastoma (See et al. 2012), melanoma (Whittaker et al. 2013), and 
ovarian cancer (Sangha et al. 2008), with implications in both disease progression and 
therapy resistance. Taking advantage of the strong expression of the TREt promoter in the 
intestinal tissues, we have crossed TtG-shNF1.6074 and TG-shNF1.8594 to the APCmin 
(Adenomatous polyposis coli multiple intestinal neoplasia) strain commonly used to study 
intestinal and colorectal neoplasms (Moser et al. 1990). Preliminary data suggests that NF1 
suppression accelerates the disease phenotype with shortened tumor-free survival (data 
now shown) and further characterization of NF1 as a candidate TSG in this model is 
ongoing.  
Multiple aspects of the work described in this chapter points towards an important 
lesson in mouse modeling: that each model system can bring challenges unique to the tissue 
type and disease under interrogation. In addition, any new element introduced into the 
model can have unpredictable consequences on the behavior of that system. Although we 
proceeded with due caution and sought to avoid drawing incorrect conclusions, it was 
unique aspects of mammary gland biology and difficulties in titrating the oncogenic force of 
tumor initiating lesions that caused a series of setbacks in adapting to the murine mammary 
gland a blueprint previously outlined in a successful hepatocellular carcinoma tumor 
suppressor screen from which this study had been fashioned (Zender et al. 2008). With the 
experience gained within our laboratory through our work with the murine mammary 
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gland and various positive selection screening platforms, we believe that future iterations of 
this project would circumvent many of the roadblocks that were encountered.  
 
CHAPTER CONTRIBUTIONS 
Uli Bialucha compiled the initial list of breast cancer tumor suppressor genes in 
collaboration with Jim Hicks and members of Michael Wigler’s group (CSHL) (Table 2.1). 
Uli Bialucha and Johannes Zuber designed the shRNAs (Table 2.2). Uli Bialucha was 
instrumental in the many aspects of the development of the screening platform (Fig 2.1b, Fig 
2.4). Alex Krasnitz developed and applied the “pinning algorithm” on the ROMA data. 
Jessica Bolden ran the Southern blot (Fig 2.13c). Sang Yong Kim performed the tetraploid 
complementation. Saya Ebbesen conducted all other experiments.  
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III. A conditional RNAi transgenic mouse model for validation and 
characterization of novel breast cancer tumor suppressor genes in vivo 
 
INTRODUCTION 
HER2 amplification and subsequent overexpression occurs in 20-30% of all human 
breast cancers and is associated with poor clinical outcome in metastasized disease (Slamon 
et al. 1987; Slamon et al. 1989; Andrulis et al. 1998; Arteaga et al. 2012). Although HER2 
mutations are rare, efforts to recapitulate this disease in genetically engineered mouse 
models (GEMMs) have focused on the use of the activated NeuNT allele under the control of 
the Mouse Mammary Tumor Virus Promoter Enhancer (MMTV), which results in the 
efficient induction of aggressive, multifocal mammary tumors (Muller et al. 1988; Bouchard 
et al. 1989). By contrast, expression of the wild type neu allele under the control of the same 
promoter gives rise to focal tumors after a much longer latency (Guy et al. 1992b). A third 
series of strains expressing the ‘neu deletion’ (NDL) transgene carrying in-frame deletions of 
the oncogene were also generated and displayed an intermediate phenotype (Siegel et al. 
1994; Siegel et al. 1999). The MMTV promoter enhancer has been shown to be hormonally 
responsive and induced during pregnancy and lactation (Henrard and Ross 1988), which 
may be problematic when studying a disease where hormonal regulation plays such a major 
role. It nonetheless remains one of the most commonly employed tissue-specific promoters 
for studies focused on the mouse mammary gland. 
The development of sophisticated RNAi technology in mammalian systems has 
produced a powerful tool for the study of TSGs in vivo. Short hairpin RNAs targeting 
relevant TSGs have been designed to hijack the endogenous RNAi machinery and to allow 
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for the stable suppression of target gene expression through mRNA cleavage or 
translational repression (Dickins et al. 2005; Silva et al. 2005; Chang et al. 2006). The use of 
an endogenous microRNA backbone, human miR-30, has enabled the technology to be 
adapted flexibly for use in vivo for both transgenic models and through ex vivo viral delivery 
prior to transplantation (Zender et al. 2008; Bric et al. 2009; Premsrirut et al. 2011). 
There are several important components that must be considered when building an 
effective in vivo tool for the investigation of genomic, molecular and cellular changes that 
occur in a developing tumor. Firstly, for affording organ specificity, one method is the use of 
tissue-specific promoters. Secondly, in most cases we seek to examine a particular 
interaction between two or more genetic lesions that are commonly found in the disease 
under investigation. Choosing the appropriate genetic background is therefore essential. For 
many cancer types the predominant or defining landscape of oncogenic changes have now 
been well characterized and can be mimicked through the overexpression of a specific 
oncogene, a mutant allele, or the disruption of a TSG. Genetic alterations that occur during 
the evolution of a tumor cell may not be simultaneous, and thus temporal flexibility and 
control can add a powerful dimension to the experimental model and tetracycline-inducible 
systems can provide that conditional control. Tetracycline inducible systems permit 
reversible perturbation of pathways, which can mimic the actions of a small molecule 
inhibitor, and help determine how addicted cancer cells have become to a particular genetic 
lesion. RNAi technology, namely the use of shRNAs for target knockdown, is an elegant 
and reversible technique for altering the protein level of a gene of interest without 
permanently altering the endogenous genomic locus. Lastly, imaging modalities such as 
fluorescence or bioluminescence can be hugely helpful in visualizing the initiation and 
progression of disease without sacrificing experimental animals, enabling longitudinal 
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monitoring and quantification. Such reporters are also beneficial for the detection of 
circulating tumor cells and metastatic growth at distal organs.  
This chapter describes efforts to bring together an existing mouse model of HER2-
positive breast cancer with the transgenic RNAi technology recently developed in our 
laboratory.  
 
RESULTS 
Multi-allelic model for achieving tissue specific expression of shRNA and incorporation 
of fluorescent markers 
With the goal of building a transgenic mouse model that allowed for the temporally 
regulated, reversible expression of shRNAs in the mammary epithelium, we conceived of 
the following multi-allelic strategy [Figure 3.1]. To achieve the desired tissue-specificity, we 
chose the whey acidic promoter (WAP) driven Cre recombinase strain (Wagner et al. 1997). 
Three different promoter systems have been commonly used for studies on the mammary 
gland: MMTV-Cre (mouse mammary tumor virus) (Wagner et al. 1997; Wagner et al. 2001), 
BLG-Cre (beta-lactoglobulin) (Selbert et al. 1998), and WAP-Cre. The WAP promoter is 
induced during lactation following pregnancy during nursing [Figure 3.1a]. Once expressed, 
Cre recombinase can act on the LoxP-Stop-LoxP (LSL) cassette embedded within a CAGs-
LoxStopLox-rtTA3-ires-mKate2 (RIK) allele (J. Pelletier and L. Dow, unpublished) [Figure 
3.1b]. The RIK transgene contains a cytomegalovirus (CMV) early enhancer element and 
chicken beta actin (CAG) promoter upstream of the LSL, followed by a modified rtTA with 
increased dox-sensitivity (rtTA3), internal ribosomal entry site (IRES) and the fluorescent 
protein mKate2. mKate2 is a monomeric far-red fluorescent protein that was designed for 
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imaging in living tissues (Shcherbo et al. 2009). Importantly, it is three-fold brighter than the 
previously published mKate protein and 10-fold brighter than mPlum. 
The CAGs promoter expresses ubiquitously in most mouse tissues and can therefore 
drive widespread expression of downstream transgenic elements (Sawicki et al. 1998). Since 
the lactation-induced WAP promoter has already provided the tissue specificity, we opted 
for the use of a promoter upstream of the rtTA element whose expression levels would be 
unlikely to be modulated by changes in cellular differentiation/dedifferentiation during the 
course of tumorigenic transformation.  
Once the luminal cells of the mammary ductal epithelium have begun expressing 
rtTA3, dox can be used to induce expression of the shRNA transgenic allele (TRE-GFP-
miR30) (Premsrirut et al. 2011). In this Tet-On set-up, the tetracycline-responsive element 
promoter (TRE) is active when bound by rtTA [Figure 3.1c]. In a similar fashion to the 
shRNA vectors described in Chapter 2, GFP has been coupled with the expression of the 
shRNA. However, while GFP reporter expression in the context of the MLS retroviral vector 
serves to confirm the presence of the shRNA construct, here the strength of the fluorescent 
signal corresponds inversely to the knockdown level of the target protein (Premsrirut et al. 
2011).  
Lastly, in line with our decision to model HER2-positive breast cancer in Chapter 2, 
we overlaid the three transgenic alleles described above onto the oncogenic background of 
the viral MMTV promoter driven mutant rat ortholog of HER2, neuV664E (MMTV-NeuNT) 
(Muller et al. 1988) [Figure 3.2a]. This mutated form of neu has a point mutation in its 
transmembrane domain that results in increased receptor homodimerization and 
constitutive activation of the kinase domain even in the absence of a ligand. It should be 
noted that we acquired the founder strain “TG.NK” available through the Jackson 
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Figure 3.2 Transgenic strains and experimental timeline for induction of alleles. (A) Simpli-­
fied schematic of breeding stretegy that incorporates five strains for the production of litter-­
mate controls along with experimental mice. (B) Timing of pregnancy, duration of lactation, 
and start of dox treatment; the designation “experimental age” in later figures corresponds to 
age of mice normalized to the date of birth of litter.
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Laboratory (http://jaxmice.jax.org/), while most of the characterization shown in the 1988 
publication focuses on strain “TG.NF”. This latter strain displayed a significant ectopic 
expression of the transgene in male mice, notably in the salivary gland and epididymis 
(Muller et al. 1988). 
We had previously attempted to use the MMTV-tTA allele to drive shRNA 
expression over the MMTV-NeuNT background but these experiments gave mixed results, 
notably a very long latency and incomplete tumor penetrance within cohorts (data now 
shown) (Hennighausen et al. 1995). While there are advantages of using a Tet-Off system, 
such as increased precision in the timing of target protein re-expression and reduced levels 
of possibly deleterious lingering dox molecules (Riond and Riviere 1988; Anders et al. 2012), 
and additionally the MMTV-tTA allele circumvented the need for pregnancy in the 
experimental outline, we remained unsatisfied with variable disease phenotypes observed.  
 
Breeding strategy for efficient production of multi-allelic experimental mice with 
appropriate littermate controls 
A well-planned strategy for mouse husbandry is important in allowing the efficient 
production of experimental animals. Since the objective is to study breast cancer, and the 
model system requires pregnancy, only females are useful for analysis. To minimize 
production of unnecessary mice, the best strategy was to first create breeder mice that 
contain two copies of each transgene such that all female pups that are born can be used for 
experimentation. In the current mouse model, we are fortunate that all of the alleles can be 
maintained in a homozygous state without loss of viability or fertility, although 
homozygous, parous MMTV-NeuNT females have a greatly shortened lifespan due to early 
tumor onset. 
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The multi-allelic model was built without undergoing the time-consuming process of 
backcrossing each transgenic strain onto the same mouse strain background. While the 
MMTV-NeuNT allele is on an FVB/n background, WAP-Cre is C57BL/6. RIK and the TG-
shRNA lines were derived using F1 hybrid ESCs that are composed of 129 and C57BL/6. 
Interbreeding these mice introduced three strain backgrounds into the experimental cohort 
and the proportion at which each strain contributed to any particular animal could not be 
measured. To control for the variable effects of strain background on disease phenotypes 
(Linder 2006; Serpi et al. 2013), we sought to follow a tactic where a control shRNA strain is 
integrated into the breeding scheme from the start. By creating compound homozygous 
animals carrying one experimental and one control shRNA, both targeted to the ColA1 
locus, we could produce litters that segregated the shRNAs in a Mendelian fashion (Linder 
2006; McJunkin et al. 2011; Dow et al. 2012). We currently have two neutral shRNA control 
strains that are routinely used: Renilla-Luciferase.713 (RLuc.713) and Luciferase.1309 
(Luci.1309) [see TABLE 6.1 in Materials and Methods]. While the shRNA-Luci.1309 targets 
the luciferase gene, the RLuc shRNA has the advantage of being compatible with in vivo 
luciferase imaging as it does not repress the reporter and has been used as the control strain 
in the experiments described in Chapter 4 (Premsrirut et al. 2011) [Figure 3.2a]. In addition 
to having no known target in the mouse genome, RLuc.713 was chosen for its high level of 
efficient expression and processing (Zuber et al. 2011a). 
 
Experimental timeline for induction of WAP-cre allele and shRNA knockdown 
The WAP-Cre transgene has a Cre recombinase cDNA driven from the promoter 
region of the murine whey acidic protein (Wap) gene that is expressed in mammary epithelial 
cells in response to lactogenic hormones. High-level expression of the endogenous Wap gene 
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is confined to the last few days of pregnancy and lactation, while robust activity of the 
WAP-Cre transgene was detected as early as day 14 of pregnancy and most strongly during 
lactation (Wagner et al. 1997). The original publication reports that cells with efficient Cre 
activity were observed after involution, a process whereby much of the terminally 
differentiated epithelial cells have undergone apoptosis during the remodeling of the gland.  
The molecular and cellular effects of pregnancy have been successfully mimicked in 
mice using hormone pellets (Ingberg et al. 2012). However, as there was no literature citing 
the use of hormones to mimic lactation we opted to use traditional husbandry and nursing 
as a means of activating the WAP-Cre transgene. 
With the understanding that many of the cells that activate WAP-Cre inevitably die 
during post-lactation involution, we decided upon an experimental timeline that 
incorporated a full three-weeks of nursing after pregnancy. Experimental females with the 
four alleles – MMTV-NeuNT ; RIK ; WAP-Cre ; TG-shRNA – began mating at 
approximately 7 weeks of age when sexual maturity had been reached. They were housed in 
proximity to male mice prior to mating to help maintain regular estrus cycling. Although 
the mice were harem mated, each pregnant female was separated into a new cage before the 
birth of her litter, thus exact litter counts and any potential difficulties in lactation could be 
noted [Figure 3.2b]. The gestation period of a mouse pregnancy can vary between 18-22 
days. The experimental mating colony was monitored daily and in most cases the 
experimental female was placed on dox treatment within 24 hours of litter birth to induce 
expression of the shRNA. After the experimental litters were weaned 21 days after birth, the 
mothers were housed randomly and remained continuously on dox treatment unless 
otherwise noted. Palpation for tumors began one week following weaning, though it was 
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rare that palpable tumor growth was observed during the first four weeks of dox treatment 
in any of the experiments described in Chapter 4. 
The use of Adeno-Cre in place of the WAP allele was tested in the abdominal 
mammary fat pads of RIK mice by direct injection into the fatty tissue near the base of the 
ductal tree [Figure 3.3]. Further improvements to this approach could involve the use of 
direct intraductal injection of the virus through the nipple, a technique we would like to 
explore further in the future (Vonderhaar and Ginsburg 2000; Behbod et al. 2009). The use of 
the viral Cre could potentially activate the shRNA in a different set of epithelial cells. This 
could result in altered tumor phenotypes or differentiation, and would also reduce the 
number of cells in which the shRNA is expressed, perhaps better modeling physiological 
heterogeneity, although at the expense of variable transgene penetrance. 
In Chapter 4, we will discuss control cohorts consisting of MMTV-NeuNT ; RIK ; 
WAP-Cre ; TG-shRNA mice that were kept as virgins but placed on dox at 10-11 weeks of 
age to approximate the treatment of the regular parous cohorts. These mice were included 
primarily to control for ectopic expression of the WAP promoter in the absence of 
pregnancy. Although the levels were insufficient to accelerate tumor onset over 
background, we did observe GFP positive ductal epithelium in some mice (data not shown). 
The timing of this ectopic activation was not investigated further. In the experiments 
described at the end of Chapter 2 in the context of modeling NF1 tumor suppressive gene 
function, parental breeders with only one copy of WAP-Cre were used to generate 
littermates that harbored either a control or experimental shRNA, with or without the Cre 
allele. This allowed for the incorporation of controls that could undergo pregnancy and dox 
treatment in the same fashion as the experimental cohorts, thus normalizing the effects of  
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pregnancy on the mouse and on the MMTV-NeuNT transgene expression levels and 
patterns.  
The mouse has five pairs of mammary glands that extend from the neck region all 
the way to the groin [Figure 3.4]. The mammary epithelial tissue does not begin to develop 
until puberty, at approximately 4 weeks of age and the full ductal branching is achieved at 
about 8 weeks. Since both the WAP-Cre and the MMTV-NeuNT transgenes express 
ubiquitously in all of the mammary tissue of the mouse, monitoring for tumor onset was 
conducted by weekly palpation of the thoracic and abdominal regions of each mouse. 
Anesthesia was used in cases where the precision of palpation while scruffing the animal 
was compromised. To facilitate the longitudinal monitoring of tumor onset and growth, a 
“quadrant system” was devised to section the mammary glands into four regions [Figure 
3.4]. In this manner, tumor onset was scored separately for each quadrant and the number 
of tumor bearing quadrants could used to grossly approximate disease penetrance and 
progression.  
 
Characterization of the MMTV-NeuNT ; RIK ; WAP-Cre ; TG-shRNA transgenic model: 
luminal epithelial expression, in vivo imaging and single transgene controls 
Successful luminal expression of the RIK transgene after recombination by the WAP 
promoter driven Cre was first assessed by fluorescence activated cell sorting (FACS) using 
cell surface markers. A cohort of age-matched mice was prepared as shown in Table 3.1. The 
tri-allelic MMTV-NeuNT ; RIK ; WAP-Cre mice were littermates and biological replicates 
were used for the parous category. For parous animals, excess pups were euthanized to 
allow for normalization of litter size to 5-6 pups that were weaned after 21 days of nursing 
[Figure 3.5a].  
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Table 3.1  Experimental categories for model characterization by FACS 
Strain Virgin Parous 
MMTV-NeuNT ; RIK ; WAP-Cre ✓ ✓ 
MMTV-NeuNT ; RIK ✓ ✓ 
WAP-Cre ✓ ✓ 
C57BL/6 ✓  
 
 
Non-invasive, optical in vivo imaging was conducted using a Xenogen IVIS® 
Spectrum. The fluorescence marker associated with the expression of RIK, mKate2, 
displayed robust tissue penetration through the skin in areas where the fur had been 
removed [Figure 3.5b]. We observed a decrease in the fluorescence signal in the weeks 
following litter weaning due to involution of the mammary gland. Additionally, the 
expression patterns of the GFP reporter from the TG-shRNA allele were also confirmed for 
tissue penetrance using a separate cohort of mice [Figure 3.5c].  
For FACS analysis, mammary glands were harvested 21 days after the end of 
lactation, a total of six weeks after litter birth. We postulated that all effects of involution 
and tissue remodeling would be complete at this time point, thus providing an accurate 
portrayal of the recombined cells that would remain in the gland. The cell surface markers 
CD24 and CD29 were used to define the luminal lineage of the mKate2 positive sub-
population of the mammary epithelial cells [Figure 3.6]. Virgin controls showed almost no 
mKate2 positivity.  
In the first iteration of the model, we chose to test the behavior and oncogenic 
background of the published transgenes in our own hands. MMTV-NeuNT+/- mice on a 
FVB/n, C57BL/6 hybrid background were generated, as well as MMTV-NeuNT+/- ; RIK+/- 
and MMTV-NeuNT+/- ; RIK+/- ; WAP-Cre+/- females on a mixed 129, FVB/n, C57BL/6 
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background that best resembled the undefined final strain composition of experimental 
cohorts described in Chapter 4. Additionally, C57BL/6 wild type mice and WAP-Cre+/- mice 
were prepared. Although these mice were not administered a dox treatment, some were 
kept as virgins and others underwent one pregnancy [Table 3.2]. To normalize for the 
variable age at which animals became pregnant (7-16 weeks; average 8.3 weeks), the term 
“experimental age” was used to refer to the time following the day of birth of her first litter. 
This nomenclature will apply to all experiments described in Chapter 4. As expected, the 
controls with no oncogenic transgene (C57BL/6 and WAP-Cre only) did not develop any 
tumors within the timeframe of this experiment (over 230 days in experimental age). Parous 
animals with MMTV-NeuNT remained tumor free on an average of 180 days in 
experimental age [Figure 3.7]. 
 
Table 3.2  Control cohorts: characterization of allelic components, background latency 
Strain Virgin (n) Parous (n) 
MMTV-NeuNT ; RIK ; WAP-Cre 5 12 
MMTV-NeuNT ; RIK 4 4 
MMTV-NeuNT 3 4 
WAP-Cre 2 7 
C57BL/6 5 3 
 
 
The experimental terminal disease endpoint, determined by unbiased assessment of 
veterinary staff, was established as any adult mouse with a tumor size exceeding 20mm at 
the largest diameter. Ulcerated tumors were also a cause for euthanasia irrespective of 
tumor size. However, this definition had its caveats for the purposes of our experiments. 
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Firstly, the location of the tumor greatly influenced the distress caused to the animal, as well 
as visibility during routine checks by veterinary staff. Secondly, the MMTV-NeuNT model 
can give rise to blood-filled cysts that can balloon quickly but do not share the same disease 
phenotypes or consequences as more solid, epithelial primary tumors. Thirdly, in the 
presence of a cooperating shRNA, the model produced mice with a tumor burden 
representing the sum of many tumors within one animal (discussed further in Chapter 4).  
 
DISCUSSION 
We have generated and tested a new transgenic mouse model for the study of HER2 
positive breast cancer that incorporates inducible RNAi technology, fluorescent reporters, in 
vivo imaging capacities, and restricted transgene expression in the luminal sub-
compartment of the mammary epithelium. The multi-allelic model makes use of the WAP-
Cre allele’s tissue specificity and induction through lactation to temporally and spatially 
restrict the expression of the GFP-tagged shRNAs via the RIK allele, which allows for strong 
and sustained expression of the rtTA3 and mKate2 elements. The dual fluorescent marker 
system is particularly powerful in experiments taking advantage of the reversibility of the 
shRNA allele. While the GFP protein level inversely correlates to target knockdown, mKate2 
tracks all cells that can express the shRNA regardless of the doxycycline treatment regimen. 
This is invaluable for tumor maintenance studies, as will be discussed further in Chapter 4. 
mKate2 expression as a Cre lineage tracer is also particularly relevant in this model where 
expression of the sensitizing oncogene, mutant neu, can drive tumor growth in cells that do 
not express the WAP promoter – these tumors are easily distinguished by absence of 
mKate2.  
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There are several distinct advantages and caveats to the model that should be noted. 
Two major advantages are the capacity to control the timing of shRNA induction and the 
near absence of ectopic tissue expression. In contrast, our experience with the MMTV-tTA 
allele were mixed. We saw high levels of GFP expression in the salivary gland and a low 
disease penetrance at long latency despite the presence of NeuNT and an shRNA targeting a 
potent TSG. It is possible that the two MMTV alleles – MTV-NeuNT and MMTV-tTA – had 
only a small overlapping cell population despite being driven from the same viral promoter, 
or that modulation of the transactivator expression levels caused by cyclical hormonal 
effects was deleterious towards sustained target gene suppression. A recent publication by 
Wagner and colleagues describes a novel MMTV-tTA transgenic strain with which it might 
be interesting to repeat the original experiments (Sakamoto et al. 2012). Additionally, we are 
looking into the possibility of testing the MMTV-cre strain in combination with our RIK 
allele in future iterations of this breast cancer mouse model. One caveat of our model is the 
dependency on pregnancy to induce lactation and expression of the shRNA allele. This 
makes the process more labor intensive and restricts our studies to sexually mature, parous 
animals; yet, the incidence of breast cancer is markedly higher in older women, many who 
have undergone one or more pregnancy. 
Multi-allelic models such as this one rely heavily on the overlapping expression of 
various promoters in the cell type of interest, at the accurate and desired time in 
development, and with as little ectopic tissue expression as possible. The transgenes have 
been engineered to the best of our capacity to ensure the reliable expression of all essential 
elements: shRNA, oncogene, rtTA, and fluorescent markers. However, the robustness of the 
model can only be tested through actual experimentation as unexpected phenotypes are 
routinely observed. Even within our research group, we have seen examples of transgene 
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‘silencing’ and other unexpected dosage effects that are not easily explained (McJunkin et al. 
2011). The RIK and TRE-GFP-miR30 strains are based on the integration of transgenic 
elements into a known locus of the mouse genome. This is preferable for several reasons but 
namely because disruption of housekeeping genes can be definitively avoided and cross-
comparison of mouse strains, for example in an allelic series or between two shRNAs, can 
be conducted more reliably. Founder mice that are made through pronuclear injection are 
usually tested thoroughly as variable sites of integration can have dramatic “founder 
effects” on the expression levels and patterns of the same transgenic element (Lin 1966; 
Muller et al. 1988).  
While some promoters are chosen for their tissue or cell-type specificity, others are 
incorporated because of their broader expression potential. In the system developed here, 
we are depending on the robust and efficient expression of the WAP promoter, and 
subsequently require linked CAGs and TRE promoter activity in the same luminal cells. 
Additionally, in order to observe cooperation of the shRNA target with NeuNT 
overexpression, we need to have sufficient, overlapping expression of TRE with the MMTV 
promoter at its particular genomic integration site. During some preliminary experiments to 
test the fluorescence compatibility of our model for intravital microscopy with the Egeblad 
laboratory in CSHL, we made the unexpected observation that a small percentage of cells 
that express the cre-excised RIK allele do not express the TRE-GFP-miR30 allele [Figure 3.8]. 
We have not yet quantified the prevalence or investigated the cause of this phenomenon 
since we do not believe it impacts our immediate experimental needs. It is nonetheless 
another reminder of how any new mouse model must be carefully tested and vetted before 
they can be used to probe meaningful hypotheses and draw accurate conclusions. It also 
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motivates us to set up platforms that will allow for faster and more systematic methods of 
model building. 
To this end, and to maximize the potential for the assessment of breast cancer gene 
function in vivo, we hope to pursue a secondary project in the future where we will re-derive 
ESCs from multi-allelic breast cancer GEMMs such as the one described in this chapter. The 
use of ESC re-derivation in cancer mouse models has been pioneered by Jonkers and 
colleagues at the Netherlands Cancer Institute (Huijbers et al. 2011) and members of our 
laboratory (Premsrirut et al. 2011; Dow et al. 2012). Our ESCs would be pre-engineered to 
harbor various cancer predisposing alleles, imaging reporters, and tetracycline-regulated 
transactivators, to which we would apply our transgenic in vivo RNAi technology pipeline 
to add the component of inducible, reversible suppression of endogenous genes directly 
into these GEMM-ESCs through ex vivo manipulation. We believe that bringing together 
these two technologies, ESC re-derivation and RNAi, will make transgenic breast cancer 
mouse modeling an even more flexible and scalable exercise as multiple combinations of 
cooperating genetic legions could be readily analyzed in parallel and the effects of tissue-
specific transient gene activation or inhibition could be assessed at different stages of 
disease using reversible, inducible alleles. This strategy has the potential to permit the rapid 
generation of breast cancer mouse models while bypassing the bottlenecks of traditional 
breeding approaches. Importantly, this method would also allow for the scalable production 
of age- and gender- matched experimental animals. Other members of the Lowe laboratory 
have been working to adopt this strategy in the context of pancreatic cancer (Saborowski, et 
al. In preparation) and colon cancer (L. Dow, unpublished), with the shared objective of 
making the translation of cancer genomic data to the clinic a faster process and to eventually 
change the standards of preclinical drug trials conducted in mice. 
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other experiments. 
 !  
 86 
 IV. Exploration of ERBB2 and PTEN as cooperating events using a novel 
inducible PTEN shRNA transgenic mouse  
 
INTRODUCTION 
In 1998 the targeted therapeutic agent trastuzumab, developed by Genentech (brand 
name Herceptin®), was approved by the US Food and Drug Administration for the 
treatment of HER2/neu-overexpressing breast cancer (Fendly et al. 1990; Robertson 1998). 
The recombinant, humanized anti-p185HER2 monocolonal antibody had cytostatic growth 
inhibitory effects on breast cancer cells overexpressing HER2 and enhanced the cytotoxic 
effects of chemotherapeutic agents in preclinical models (Baselga et al. 1998). HER2 has been 
found overexpressed in 20-30% of human breast cancers and leads to an aggressive disease 
with poor patient survival (Slamon et al. 1987; Yu and Hung 2000). Early clinical trials 
showed trastuzumab was active when used in conjunction with existing chemotherapy, and 
that the combination significantly prolonged the median time to disease progression, 
increased the overall response rate, increased the duration of response, and improved 
median survival time by approximately 25% compared to the use of chemotherapy alone 
(Cobleigh et al. 1999; Baselga 2001; Seidman et al. 2001; Slamon et al. 2001; Esteva et al. 
2002). However, these trials reported less than 35% of patients with HER2-overexpresisng 
metastatic breast cancer responding to the drug as a single agent (Cobleigh et al. 1999; Vogel 
et al. 2002). 
Despite over a decade of active research, an incomplete understanding of the 
mechanism behind trastuzumab’s antitumor activity remains. Early studies suggested as 
possible mechanisms of action the downregulation of HER2 (Petit et al. 1997), the induction 
of antibody-dependent cellular cytotoxicity (ADCC) (Clynes et al. 2000), an induction of G1 
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arrest and the cyclin-dependent kinase inhibitor p27kip1 (Sliwkowski et al. 1999), or the 
inhibition of HER2 extracellular domain cleavage preventing the production of an active 
truncated HER2 fragment (Molina et al. 2001). Inhibition of PI3K/Akt signaling has also 
been implicated, with studies demonstrating a downregulation of HER2 signaling (Hudziak 
et al. 1989; Yakes et al. 2002) or an increase in PTEN membrane localization and 
phosphatase activity leading to a decline in PI3K/Akt pathway activation and consequently 
an inhibition of proliferation (Nagata et al. 2004). This last study by Nagata and colleagues 
not only showed that PTEN antagonizes tumorigenesis but also sensitizes breast cancers to 
trastuzumab treatment.  
The tumor suppressor gene PTEN opposes the activation of the proto-oncogenic 
PI3K/Akt signaling pathway and is found disrupted in many cancer types (Cantley and 
Neel 1999). PTEN was originally identified as a gene frequently mutated in brain, breast and 
prostate cancers through the mapping of homozygous deletions on human chromosome 
10q23 (Li and Sun 1997; Li et al. 1997; Steck et al. 1997). Early studies reported loss of 
heterozygosity (LOH) of the 10q23 chromosomal region in as many as 30-40% of invasive 
breast carcinomas, while no LOH was seen in intraductal carcinomas, thus associating the 
loss of this locus with tumor progression (Bose et al. 1998; Singh et al. 1998; Feilotter et al. 
1999; Garcia et al. 1999) 
In the classic Knudson model of neoplastic transformation, a tumor suppressor gene 
begins with a somatic or inherited mutation in one allele, to which the subsequent loss of the 
other allele causes a selective proliferative or survival advantage (Knudson 1971; Cavenee et 
al. 1983; Knudson 2001).  However, numerous TSGs, including TP53 and PTEN, have been 
shown to exhibit haplo-insufficiency due to dose-dependent anti-tumorigenic functions 
(Berger and Pandolfi 2011). Pten hypermorphic mice, expressing 80% of normal Pten protein 
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levels, develop a spectrum of tumors but notably, breast tumors occur with the highest 
penetrance (Alimonti et al. 2010). 
PTEN normally opposes the activation of phosphatidylinositol 3’ kinase (PI3K) 
through cleavage of the D3 phosphate of phosphatidylinositol (3,4,5)-triphosphate (PIP-3), 
its main substrate (Maehama and Dixon 1998). Loss of PTEN function therefore results in 
AKT hyperactivation that leads to protection from various apoptotic stimuli (Stambolic et al. 
1998). Early studies in mouse models demonstrated that the inactivation of even one Pten 
allele could lead to a dramatic impact on the survival and proliferative capacity of cells (Di 
Cristofano et al. 1999). It has been suggested that PTEN plays an essential and cell-
autonomous role in regulating the proliferation, differentiation and apoptotic functions of 
mammary epithelial cells as conditional loss of PTEN in the mammary gland gives rise to 
precocious lobulo-avelolar development, excessive ductal branching, delayed involution 
and severely reduced apoptosis (Li et al. 2002).  
With the goal of improving the availability of biomarkers that accurately predict 
responses to cancer therapy vital to the rational use of cancer drugs in the clinic, Berns and 
colleagues used a HER2-overexpressing breast cancer cell line BT-474 and conducted a 
large-scale RNAi genetic screen using a library of 24,000 shRNA retroviral vectors targeting 
8000 human genes (Berns et al. 2007). BT-474 cells are sensitive to treatment by trastuzumab 
and respond by a reduction in proliferation. PTEN knockdown was the only gene loss that 
conferred resistance to the drug, in line with previous observations (Nagata et al. 2004). 
Fujita and colleagues also published similar findings where changes in sensitivity to 
trastuzumab in SKBR3 cells were examined with and without PTEN knockdown by siRNAs 
(Fujita et al. 2006). 
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Reduced or complete loss of PTEN expression has been documented in 30% of 
relapsed sporadic IDCs and primary ductal adenocarcinomas (Perren et al. 1999; Jones et al. 
2013), in over 50% of patients treated with tamoxifen as single adjuvant therapy (Tanic et al. 
2012), and as mentioned above, LOH of 10q23 has been repeatedly reported to be found in 
over 40% of invasive carcinomas. However somatic intragenic mutations in PTEN are only 
observed in a fraction of primary breast cancers (frequency <5%) (Saal et al. 2005), making it 
is unlikely that PTEN loss of function alone can serve to explain the frequent primary and 
acquired resistance to trastuzumab seen in patients (Nagata et al. 2004; Berns et al. 2007; 
Gallardo et al. 2012). However, loss of function mutations in PTEN or decreased PTEN 
expression lead to a hyperactivation of the PI3K pathway, and PI3K pathway activation can 
result from other, more frequent events found in breast cancer such as activating mutations 
in the p110a catalytic subunit of PI3K (PIK3CA) that occur in approximately 25% of primary 
breast cancers (Saal et al. 2005). Additionally PTEN loss and PIK3CA mutations are rarely 
present in the same tumors (Saal et al. 2005; Berns et al. 2007; Gallardo et al. 2012), and 
increased PI3K signaling is also capable of inducing strong trastuzumab resistance in cell 
culture (Berns et al. 2007). 
Here, we have introduced an shRNA targeting Pten into our multi-allelic mouse 
model developed in Chapter 3 with the aim of generating an experimental system that may 
help further interrogate the role of the TSG PTEN in HER2 positive breast cancer disease 
progression. Mice harboring the lesions conferring PTEN knockdown and NeuNT 
overexpression show a dramatic acceleration to disease onset and progression, as well as 
shortened overall survival. There was also an increased incidence of metastatic disease in 
the lung. Lastly we show that PTEN loss is important for tumor maintenance in this model. 
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RESULTS 
PTEN shRNA knockdown accelerates NeuNT driven disease onset and progression 
Two shRNA strains targeting Pten were previously made and functionally tested in 
the context of the Eu-Myc lymphoma model (Miething, et al., In preparation). Efficient 
knockdown of the target and proper regulation of PTEN protein levels were shown in MEFs 
and in KH2 EHCs [Figure 4.1a,c]. Using the stronger shRNA strain TG-shPTEN.1522 [Figure 
4.1b], we sought to test the cooperation between PTEN knockdown and oncogenic NeuNT 
in the multi-allelic model developed in Chapter 3. The experimental protocols previously 
outlined were followed as described earlier unless otherwise noted. Accordingly, control 
shRNA mice were produced as littermates in all cases. We are still working towards testing 
the second shRNA allele, TG-shPTEN.2049, to fully validate our results described in this 
chapter. However, in addition to PTEN being a well-characterized TSG, given the extensive 
use of the shPTEN.1522 shRNA in multiple breast cancer models as well as in many other in 
vivo cancer model systems in our research group, we are confident that the phenotypes we 
observe here are not due to off-target effects of this particular shRNA. Here after “TG-
shPTEN” refers to the TG-shPTEN.1522 strain. 
Due to consequences of the move from CSHL to Memorial Sloan-Kettering Cancer 
Center (MSKCC) in August 2011, the following in vivo experiments were performed twice, 
with as few changes introduced as possible in the replicate round [Table 4.1]. An 
acceleration of disease was seen in terms of tumor onset, with a shortened latency of tumor-
free survival for mice carrying TG-shPTEN [Figure 4.2], and this was accompanied by a 
decreased overall survival [Figure 4.3]. The quadrant scoring system was used to define loss 
of tumor-free survival – a tumor in any area of the animal meant a classification as tumor 
bearing – and each quadrant was tracked separately. A faster progression from tumor-free 
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Table 4.1  Experimental variables for shRLuc and shPTEN experimental cohorts  
 
Variable CSHL  
TG-shRLuc 
 
TG-shPTEN 
MSKCC 
TG-shRLuc 
 
TG-shPTEN 
Age at litter birth 
(days) 
average  76.2 
range      67~137 
77.3 
58~107 
74.4 
65~113 
75.9 
67~110 
Litter size average  7.8 
range       3~12 
8.2 
5~10 
7.0 
1~11 
7.5 
2~11 
Experimental age(*) at  
start of dox treatment** 
average  1.4 
range      -3 ~ 8 
1.1 
-6 ~ 7 
0 
0 ~ 1 
0 
0 ~ 2 
Lactation duration average  20.9 
range      19-22 
20.8 
18-22 
21.0 
20-22 
20-24 
21.1 
Litter loss*** 
(% cohort) 
0% 
 
0% 4.4% 6.6% 
Unrelated death**** 
(% cohort) 
2.6% 
 
0% 15.9% 3.3% 
All animals listed here are parous MMTV-NeuNT ; RIK ; WAP-Cre ; TG-shRNA animals 
*Experimental age defined as day of litter birth for parous animals 
**For mice under regular dox treatment protocol, where treatment begins simultaneously with nursing 
***Incidence of successful pregnancy and birth of litter followed by cannibalization or starvation of pups 
****Deaths in young mice unrelated to breast tumorigenesis, usually during or soon after the period of lactation 
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HR = 18.68
95% CI (8.245 to 42.31)
Log-rank (Mantel-Cox) Test
p < 0.0001
Median survival:
   TG-shPTEN    72 days
   TG-shRLuc    159.5 days
HR = 24.43
95% CI (12.29 to 48.58)
Log-rank (Mantel-Cox) Test
p < 0.0001
Median survival:
   TG-shPTEN    62 days
   TG-shRLuc    168 days
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Median survival:
   TG-shPTEN    108 days
   TG-shRLuc     207 days
HR = 79.42
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Median survival:
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to a full four-quadrant penetrance of the disease was observed for TG-shPTEN mice [Figure 
4.4a, 4.5]. This overall increase in tumor burden and penetrance was also quantified through 
the final quadrant penetrance at terminal disease endpoint and tumor burden in weight at 
harvest [Figure 4.4b,c].  
As the data show, the combined effect of PTEN knockdown and NeuNT 
overexpression causes disease latency to be halved, all the while dramatically increasing the 
number of tumors found in each experimental animal. Additionally, while every tumor 
harvested from mice harboring the TG-shPTEN allele has been GFP positive, in TG-shRLuc 
mice only a small fraction of the tumors display fluorescence (less than 25%), indicating that 
PTEN knockdown is driving tumor growth in a WAP promoter expressing subpopulation 
of epithelial cells that are not per se the cell of origin for many of the MMTV-NeuNT allele 
driven tumors [Figure 4.6]. We concluded that the multifaceted aspect of the model’s tumor 
growth patterns did not allow for precise quantification of tumor burden via in vivo 
fluorescence imaging, but it remains a powerful component of the system that can be used 
for longitudinal studies [Figure 4.7]. 
Although some preliminary controls had been tested in Chapter 3, there remained 
some uncertainty regarding which parts of the multi-allelic model would require extra 
controls. During the first round of experimentation at CSHL, we modulated the pregnancy 
status, the presence of WAP-Cre and the dox treatment in a number of small control cohorts 
to better pinpoint any weaknesses in the system [Table 4.2]. Through these controls we 
found that WAP-Cre expresses at basal levels in the absence of lactation in the mammary 
ductal epithelium, and that it also occasionally expresses ectopically in other tissue types 
such as the muscle tissue of the lung (data not shown). These control mice also served to test 
the efficiency of the pregnancy protocol and establish the latency of parous MMTV-NeuNT 
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mice with a heavy contribution of C57BL/6 in their strain background. In our hands we find 
that the onset of NeuNT-driven disease is parity dependent [Figure 4.8].  
 
 
Table 4.2  Control conditions: CSHL cohort 
Condition Control cohort for 
Virgin, no WAP-Cre, no dox NeuNT background in mixed strain setting 
Virgin, on dox WAP-Cre allele leakiness in absence of lactation 
Parous, no WAP-Cre, on dox Doxycycline treatment control 
Parous, no dox TRE leakiness in absence of dox treatment 
Parous, on dox   Regular experimental condition 
Four alleles unless otherwise noted 
 
 
During the second round of experimentation at MSKCC, it became clear that there 
were additional variables to consider. We continued to monitor for the ectopic activation of 
WAP-Cre in the absence of pregnancy and lactation, but also modulated the timing of dox 
treatment vis-à-vis lactation [Table 4.3] [Figure 4.9, 4.10]. We found that delaying the 
induction of TG-shPTEN until after the end of lactation and involution, a period of 4 weeks, 
had an impact on the overall survival of mice, although the disease phenotype did not 
fundamentally change [Figure 4.10a]. We also included controls where MMTV-NeuNT was 
absent, to definitively distinguish a cooperative effect versus the impact of PTEN 
knockdown alone [Figure 4.9c, 4.10c]. A small cohort has only allowed for preliminary 
conclusions but thus far mice with TG-shPTEN in the absence of NeuNT (n=4) have not 
developed tumors at a latency of over 220 days in experimental age.  
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Table 4.3  Control conditions: MSKCC cohort 
Condition Control cohort for 
Virgin, on Dox WAP-Cre allele leakiness in absence of lactation 
Parous, no MMTV-NeuNT, delayed dox Effect of shRNA allele in absence of NeuNT 
Parous, no MMTV-NeuNT, on dox Effect of shRNA allele in absence of NeuNT 
Parous, delayed dox Effect of delayed shRNA induction 
Parous, on dox Regular experimental condition 
Four alleles unless otherwise noted 
 
 
Tumor pathology and primary disease phenotype 
We analyzed the tumors through immunohistochemistry to gain some insight into 
the disease architecture at a cellular level. PTEN protein knockdown was consistently very 
robust in tumor tissue, which concurrently showed strong expression of GFP and mKate2. 
These areas also displayed strong staining for Neu/ErbB2 at the cell membrane and a high 
Ki-67 index, a marker for cellular proliferation [Figure 4.11]. In order to better characterize 
the molecular phenotype of the primary tumors, the expression pattern of luminal 
(CK8/CK19) and myoepithelial (CK5/CK14) markers, as well as epithelial-mesenchymal 
transition (EMT) markers vimentin and E-cadherin, is ongoing. Characterization of the 
hormone receptor status (ER/PR) of the tumors is also in progress.  
We observed strong nuclear pleomorphism (3 points), a high mitotic count (3 points) 
and lack of tubule formation (3 points) by hematoxylin and eosin (H&E) staining of tumor 
sections. With a total sum of 9 points, the tumors were classified as resembling most closely 
a high grade, poorly differentiated tumor type with poor prognosis in humans [Figure 4.12]. 
With a histological likeness to patient biopsies diagnosed as “invasive ductal carcinoma, not 
otherwise specified (NOS)”, these NeuNT-driven tumors correspond to the most common 
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type of malignant breast tumor seen in the clinic. There were no differences observed 
between shRLuc and shPTEN tumors harvested at terminal disease endpoint. Other features 
observed included large areas of necrosis, reactive stroma and evidence of ductal carcinoma 
in situ (DCIS) in intact mammary glands with early lesions. ErbB2/neu transgenics have been 
previously reported to frequently present microscopic fields that can be easily mistaken for 
human DCIS (Cardiff and Wellings 1999; Cardiff et al. 2000). 
 
Characterization of disseminated disease 
Using the fluorescent reporters we were able to track spontaneous disseminated 
disease to the lung, liver, bone, and spleen of TG-shPTEN animals [Figure 4.13]. Metastasis 
to the lung was most frequent, observed in 100% of TG-shPTEN mice, while lesions in the 
liver and bone were more rarely observed. If present, micromets observed in the liver were 
very small and would have not been detected if not for the fluorescent markers integrated 
into the model. Infiltration of GFP positive cells in the spleen was noted at a high frequency 
in mice with high tumor burden. We attributed this phenotype to a likely large quantity of 
circulating GFP positive tumor cells. Immunohistochemical analysis was performed on lung 
metastatic tumor sections to verify PTEN protein knockdown and expected expression of 
fluorescent markers [FIGURE 4.14]. Similar to the primary mammary tumors, there was also 
strong Neu/ErbB2 and Ki-67 staining. The frequency of metastasis were harder to quantify 
in control mice since GFP positive cells comprised only a fraction of the tumor burden, 
making the detection of small mets less accurate.   
The highly epithelial and ductal morphological resemblances between primary lung 
tumors and lung metastasis of mammary origin is a confounding diagnostic problem in the 
clinic (Yang and Nonaka 2010). The immunohistochemical pattern of expression of thyroid  
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transcription factor 1 (TTF1) is an established clinical marker used to aid in accurate 
diagnostic distinction between primary and metastatic pulmonary adenocarcinomas, 
although some controversy over specificity and clinical effectiveness still remains (Reis-
Filho et al. 2000; Moldvay et al. 2004; Zhu and Michael 2007; Maeshima et al. 2008). Staining 
of lung lesions with TTF1 is ongoing. Additionally, we have begun probing the lung 
sections with luminal and myoepithelial markers for cross-comparison to their respective 
primary tumors, and we will also stain for hormone receptors, which are traditionally 
associated with mammary tumors (Tennis et al. 2010).  
Histological assessment of lung mets based on H&E staining indicated cell 
morphology, high mitotic index and undifferentiated growth patterns that drew a very close 
resemblance to the primary mammary tumors, providing additional confirmation that the 
observed phenotype was in fact invasive, spontaneous metastasis originating in the 
mammary gland [Figure 4.14]. 
 
In vitro culture of tumor-derived cells and in vivo serial transplantation 
We were successful in culturing tumor-derived cells in vitro for multiple passages in 
low serum (1%) and low oxygen (5-7%) conditions on gelatin-coated plates in RPMI media 
supplemented with hydrocortisone, insulin and prolactin [Figure 4.15a]. The fluorescent 
markers were used in some cases to enrich for tumor cells by FACS sorting. Cells were 
maintained on dox in vitro at all times unless otherwise noted.  
We tested the capacity for transplantation of the spontaneous mammary tumors 
from primary transgenic animals into secondary recipient mice as a potential platform for 
future experimentation (Varticovski et al. 2007). The mixed strain background prevents the 
use of syngeneic animals and consequently we opted for orthotopic transplantation into the 
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un-cleared mammary fat pads of athymic nude mice on a dox diet. Tumors were harvested 
from primary transgenics, mechanically and enzymatically dissociated to generate a single-
cell digest, and then plated overnight on gelatin-coated plates before transplantation the 
following day. In preliminary experiments, the tumor-derived cells from two independent 
TG-shPTEN animals with advanced disease (TG-shPTEN line #9 and #10) were injected and 
these cells displayed similar latency and growth patterns [Figure 4.15b]. The histological 
assessment of tumor sections stained in H&E indicated a similarly high mitotic index and a 
cell morphology resembling the primary transgenic tumors. Additionally, formation of 
glandular structures at the periphery was noted (data not shown). 
Subsequently, serial transplantation was tested. Tumors isolated from nude 
recipients were dissociated under the same conditions as before and transplanted into 
secondary recipients on a dox diet. The tumors arising from these injections showed a slight 
acceleration in growth in the secondary transplant setting compared to their first transplant 
(TG-shPTEN line #9 and #10) [FIGURE 4.15c]. Additionally, we explored the option of 
transplanting small 1mm3 tumor fragments that were frozen after tumor harvest. This 
method has the advantage of preserving the stromal architecture of the original primary 
transgenic tumor, reminiscent of the practice of xenografting patient tumor isolates from the 
clinic directly into mice (Vargo-Gogola and Rosen 2007). GFP positive tumor fragments 
from one TG-shRLuc and one TG-shPTEN mouse with advanced disease were thawed and 
inserted into the fat pads of recipient mice. Although tumors developed from fragments in 
both cases, a discrepancy was observed in the latency to tumor onset, penetrance, survival 
of transplanted animals and incidence of lung metastasis between TG-shRLuc and TG-
shPTEN [Figure 4.15d-f]. 
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PTEN knockdown is required for tumor maintenance 
The cooperation between PTEN knockdown and NeuNT overexpression was very 
robust, demonstrating an undeniable advantage in tumor initiation, progression, and 
metastasis. We next took advantage of the reversible nature of the RNAi technology to 
examine the effects of restoring PTEN protein levels in the growing tumors to ask the 
question if PTEN loss is required for tumor maintenance. 
In a pilot experiment, we monitored a parous MMTV-NeuNT ; RIK ; WAP-Cre ; TG-
shPTEN.1522 mouse that began dox treatment 21 days after giving birth to her litter, 
simultaneous with weaning of her pups. After approximately two and a half months, the 
animal presented tumors in all four quadrants. The largest tumor was surgically removed 
from the left abdominal fat pad region and dox was removed from the diet. Over the course 
of a month, the GFP signal disappeared and tumor regression was observed [Figure 4.16]. 
The in vivo fluorescence imaging showed that the abdominal right region had a tumor that 
was largely negative in reporter signal when imaged sagittally. The large quantity of bloody 
fluid in this cyst is the likely explanation for why the tumor did not show any sign of 
shrinkage. 
We subsequently conducted a small study involving five parous MMTV-NeuNT ; 
RIK ; WAP-Cre ; TG-shPTEN.1522 mice. Dox treatment was administered 4 weeks after 
litter birth (i.e. one week after the weaning of her pups). After thirteen weeks on dox 
treatment, three of the five mice were placed on regular chow and all five were monitored 
through small animal magnetic resonance imaging (MRI) [Figure 4.17]. We complemented 
this approach with caliper measurements for rapid assessment of changes in tumor burden. 
While the sum total tumor burden in the mice with PTEN knockdown continued to increase 
exponentially, with a rapid need for euthanasia, those mice with restored PTEN levels 
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showed a dramatic reduction in tumor burden during the first three weeks and a greatly 
increased overall survival. While two of the three off dox animals began to show increases 
in tumor burden after a month and a half, one mouse failed to develop any substantial 
tumor burden for over 90 days after removal of dox from the diet.  
To test whether our results would be reproducible over a larger cohort of animals, 
we followed-up with a study involving twelve parous MMTV-NeuNT ; RIK ; WAP-Cre ; 
TG-shPTEN.1522 mice that began dox treatment the day of litter birth, as described in the 
standard experimental procedure in Chapter 3. In this iteration, shPTEN.1522 mice were 
monitored through weekly palpation until the first tumor was observed. Dox treatment was 
halted two weeks after tumor onset and weekly caliper measurements were used to assess 
tumor burden. All twelve mice showed some degree of reduction in tumor burden but the 
intensity of the effect varied [Figure 4.18a]. Despite the wide range of responses, a 
statistically significant increase in survival benefit was observed, as well as a slowed 
progression in quadrant progression and penetrance [Figure 4.18b]. Control TG-shRLuc 
mice were also taken off dox to verify that the change in diet does not contribute to altered 
patterns of tumor growth [Figure 4.19a]. During these tumor regression studies fur removal 
was avoided to prevent increased stress and adverse inflammatory responses that could 
affect experimental outcomes.  
Some degree of tumor regression was also observed in transplanted recipients with 
TG-shPTEN primary tumor-derived cell lines (#9 and #10) after removal of dox [Figure 
4.19b]. In this context, the short-lived and moderate response was attributed to the large size 
of the transplanted tumors as well as their origin in primary mice with aggressive, advanced 
mammary tumors. In culture, tumor-derived cell lines did not display any significant 
changes in proliferation upon dox removal, although GFP signal steadily decreased as  
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expected over the first 7 days, indicating that the Tet-On system was still intact (data not 
shown). 
 
Exploring the mechanism of tumor regression and long term resistance upon restoration 
of PTEN protein  
As demonstrated in the experiments described above [Figure 4.17, 4.19], quantifiable 
and consistent reduction in tumor burden was observed after the withdrawal of dox from 
the diets of MMTV-NeuNT ; RIK ; WAP-Cre ; TG-shPTEN.1522 mice at early stages of 
tumorigenesis. This effect appears to diminish in mice bearing a larger tumor burden at the 
start of the experiment, and this trend persisted in the transplant setting. In early trials 
involving mice with tumor burdens nearing experimental disease endpoint, the 
documented effect was at best cytostatic, as no regression could be measured although 
tumor growth was diminished and overall survival could also be extended in these mice 
(data not shown).  
Elevated levels of necrosis is a common feature in the fast growing transgenic TG-
shPTEN tumors under dox treatment, confounding the use of necrotic features in dox 
withdrawn tumors as an index of heighted cell death. However, transplanted tumors 
display lowered rates of proliferation in the first two weeks following the removal of dox 
diet, as evidenced both in reduced staining of the proliferation index Ki-67 and a decreased 
mitotic index by histological assessment (data not shown).  
Complementing the observed slowed rate of tumor cell proliferation, we expect to 
find evidence of increased cell death in these tumors. Hyperactivation of the AKT pathway 
is expected to decline upon restored of PTEN phosphatase activity, thus leading to an 
increase in apoptotic signal. To gain a better understanding of the mechanism underlying 
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the tumor shrinkage phenotype, efforts to quantify changes in signaling, cell proliferation, 
and rates of apoptosis (cleaved caspase-3) are currently ongoing. 
In this model, MMTV-NeuNT can drive tumorigenesis in cells that do not express 
the WAP-Cre transgene, a feature that has been confirmed from the high rate of tumors 
arising in TG-RLuc mice that are negative for GFP/mKate2 fluorescence signal. 
Consequently, we expect to see the eventual appearance of NeuNT-driven tumor growth in 
TG-shPTEN animals where substantial tumor regression was initially observed upon dox 
withdrawal. Interestingly, tumors harvested from TG-shPTEN mice that suffered from 
‘resistance’ to PTEN restoration, a more complex picture emerged. In addition to the 
expected presentation of fluorescence-negative tumors, we also documented lesions that 
were mKate2+/GFP- and mKate2+/GFP(+) [Figure 4.20]. This latter category of tumors 
indicates a breakdown in the tet-regulatable machinery, since the TRE-GFP-miR30 allele is 
being expressed in the absence of dox, albeit at substantially lowered levels compared to 
dox treated tumors. The most interesting set of tumors are the mKate2+/GFP- samples, 
which may be mimicking a therapy resistance phenotype. We are actively investigating 
these samples in order to identify the escape mechanism underlying the rapid growth of 
cells that had previously benefitted from the strong knockdown of PTEN. Of note, some 
mice displayed evidence of all three tumor types at tumor burden endpoint harvest. 
 
DISCUSSION 
Using our transgenic RNAi model comprising of the MMTV-NeuNT, WAP-Cre, RIK 
and TG-shRNA alleles, we were able to demonstrate a highly significant acceleration of 
mammary tumorigenesis when Pten is knocked down. The disease phenotype displayed 
shortened tumor-free and overall survival, with 100% penetrance. Additionally, there was  
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an increase in the rate and severity of the metastatic phenotype. The shortened latency was 
so dramatic that almost all of the TG-shPTEN mice had achieved terminal disease endpoint 
before tumor onset was observed in control TG-shRLuc animals. Although this finding 
serves to demonstrate the level of impact that PTEN knockdown has on NeuNT oncogene 
driven tumorigenesis, it complicated experimental analysis since tumors from TG-shPTEN 
and TG-shRLuc mice could not be harvested at the same time point for meaningful cross-
comparative analysis of disease phenotypes.  
Two publications from Bill Muller’s group had previously made similar observations 
using a conditional knockout model of Pten (Dourdin et al. 2008; Schade et al. 2009). In the 
first study, ErbB2 overexpression was driven from its endogenous promoter (ErbB2KI) and 
coupled with an MMTV-Cre that acted on the PTEN conditional knockout allele (Andrechek 
et al. 2000; Li et al. 2002). Mammary-specific deletion of PTEN resulted in a dramatic 
acceleration of ErbB2-induced tumor progression and also increased the incidence of 
metastasis to the lung. In this particular model they report that the PTEN-deficient tumors 
acquired pathologic characteristics resembling the basal-like subtype of human breast 
cancers. The study included animals with both heterozygous and homozygous conditional 
loss of PTEN. Interestingly, tumor progression was associated with LOH at the PTEN locus 
in over 50% of tumors from PTEN heterozygous null animals.  
After examination of upstream and downstream targets of PTEN and ErbB2, 
Dourdin and colleagues conclude that sustained activation of the PI3K/Akt signaling 
pathway is not the mechanism responsible for the accelerated mammary tumor formation in 
their PTEN-deficient/ErbB2KI mouse model. We plan to verify these findings in our own 
system through comparative analysis of pathway activation status in TG-shPTEN and TG-
shRLuc tumors, although potential discrepancies in findings could be explained by 
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differences in basic tumor biology arising from the molecular and histopathological 
heterogeneity described in this knockout model and the general homogeneity and luminal 
phenotype observed in our RNAi model. 
In the second study, Schade and colleagues exchanged the ErbB2KI strain for a 
system that drives transcription of an activated ErbB2/Neu from the strong viral MMTV 
promoter in a bicistronic configuration with Cre recombinase (MMTV-NIC), which couples 
the expression of the oncogene and Cre within the same mammary epithelial cells (Siegel et 
al. 1999; Ursini-Siegel et al. 2008). In line with the previous study, they report a dramatic 
acceleration of mammary tumor onset, and the development of multifocal and invasive 
metastasizing disease in mice with homozygous inactivation of PTEN in the presence of 
NeuNT. In contrast, however, they describe tumors with a homogenous morphology and a 
loss of basal and myoepithelial markers leading to histopathological and molecular 
characteristics of the luminal subtype, as well as a hyperactivation of the PI3K/Akt 
pathway. 
The variation in phenotypes conferred by the various mouse models once again 
emphasizes the importance of the fundamental model design, and how differences in the 
timing of transgene expression, subtle discrepancies in the expression levels of key 
elements, or selection of distinct cell populations may all have a profound impact on 
experimental results.  
Although we cannot circumvent the issue of highly discrepant tumor latency, some 
of the control TG-shRLuc tumors, those expressing GFP and thus resulting from the same 
luminal cell compartment as the TG-shPTEN tumors, could be used as a strong point of 
reference when examining the mechanism of cooperation behind the combined oncogenic 
effect of heightened HER2/neu signaling and PTEN impairment. Thus far the pathological 
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analysis does not indicate any differences in morphology and once developed, these control 
tumors also display fast growth and invasive capacity. Nonetheless we plan to look for 
evidence of PTEN loss and PIK3CA mutations in these tumors, as well as other possible 
changes in signaling patterns, that might point towards an explanation for the strong 
cooperation documented in these models of cooperation between PTEN loss and ErbB2/neu 
hyperactivity.  
In this regard, our inducible RNAi model presents some unprecedented 
opportunities. We have already explored one setting of delayed doxycycline treatment but 
this could be extended further to, for example, better mimic what is found in the clinic or to 
generate a series of tumor samples where the cooperating shRNA is introduced at staggered 
time points. In the knockout models discussed above and in our own current iteration 
described in this chapter, PTEN deficiency has been incorporated into the initiation of the 
tumorigenic process and this presents itself as a major caveat in the accurate portrayal of 
human tumor biology. Additionally, the employment of the mutant neu allele undermines 
our capacity to test targeted therapies against ErbB2 or ErbB3. Although the latency is 
longer, in future studies it may be preferable to switch to the wild type MMTV-neu strain 
such that our platform might serve as a better preclinical model for testing novel therapeutic 
agents. Furthermore, to gain the capacity to effectively study resistance to trastuzumab in 
the context of a GEMM of mammary adenocarcinoma, the transgenic strain overexpressing 
human HER2 (huHER2) from the MMTV promoter would need to be employed (Finkle et 
al. 2004). Genentech has developed and tested the murine form of trastuzumab, mu4D5, in 
the MMTV-huHER2 model and observed some acquired resistance although the mechanism 
was not determined. 
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Our finding that TG-shPTEN driven tumors regress upon restoration of PTEN 
protein levels suggests that heightened PI3K/Akt signaling is a critical element of these 
tumor cells’ sustained survival and proliferative advantage. However, depending on the 
size and stage of tumor growth, we observe a varied degree and length of responses to the 
reversal of PTEN knockdown. We are actively investigating the mechanisms by which these 
tumors progress through the initial phases of reduction in tumor burden followed by the 
eventual return of a highly proliferative disease. We are confident that the re-activation of 
PTEN function can be more than cytostatic and truly cytotoxic since some tumors suffer a 
substantial and long-term reduction in tumor burden. As our primary experimental animals 
are immune competent, it would be equally tempting to investigate the possible role of 
immune clearance or wound healing, as well as the involvement of other components of the 
microenvironment, that may contribute to this regression phenotype.  
Preliminary analysis of the ‘relapsed’ tumors indicates that in some circumstances 
the tumor cells have found ways to bypass the tet-regulated machinery. Mutations in rtTA 
have been previously reported in the literature (Podsypanina et al. 2008), and the presence 
of faint levels of GFP in some tumors points towards such a breakdown in the system. 
Confirmation of the rtTA mutational status, and an estimate of its prevalence, is pending. 
Tumors that display mKate2 signal but no GFP have presumably found alternative 
mechanisms of restoring the survival and proliferative advantages from which they 
previously benefitted. A thorough analysis of the downstream signaling profile of these 
tumors, as well as examination of the mutational status of PIK3CA and PTEN or a possible 
LOH of 10q23, will help to explain this ‘acquired resistance’ phenomenon.  
Previous examples of restoration of tumor suppressor function include studies in 
GEMMs of lymphoma, sarcoma and hepatocellular carcinoma, were it was demonstrated 
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that p53 restoration induced tumor cell apoptosis (lymphoma) or senescence 
(sarcoma/carcinoma) and resulted in tumor regression and clearance (Martins et al. 2006; 
Ventura et al. 2007; Xue et al. 2007). In the context of breast cancer, Boxer and colleagues 
reported a lack of sustained regression of c-Myc induced mammary adenocarcinomas 
following both brief and prolonged inactivation of the oncogene in a doxycycline-inducible 
system driving rtTA from MMTV-LTR (Gunther et al. 2002; Boxer et al. 2004). In parallel 
studies, the downregulation of neu expression in an MMTV-rtTA driven tet-regulatable 
NeuNT model resulted in tumor regression. However, mice bearing fully regressed tumors 
eventually developed spontaneous recurrences in the absence of neu expression (Moody et 
al. 2002), and the transcriptional repressor Snail was shown to be spontaneously 
upregulated and accompanied by EMT in these recurrent tumors in vivo (Moody et al. 2005). 
Virtually all targeted therapies used in the clinic today were developed on the 
principle that one oncogenic mutation can be identified and selected for treatment by a 
specific agent. This paradigm fundamentally ignores the role of cellular signaling crosstalk 
and the intrinsic plasticity of mechanisms that allow for maintained cellular homeostasis. 
Many studies have illustrated the dynamic interactions between major signaling networks, 
all emphasizing the role of feedback activation of pathways as a roadblock in attaining the 
desired therapeutic benefit of single agent targeted therapies. Inhibition of the mTORC1 
complex with rapamycin-like drugs causes activation of PI3K and AKT, thus limiting their 
clinical efficacy due to the release of a negative regulatory feedback loop that triggers AKT 
and ERK signaling (O'Reilly et al. 2006; Cloughesy et al. 2008; Tabernero et al. 2008; Baselga 
et al. 2009). Similarly, inhibition of AKT has been shown to induce the expression and 
phosphorylation of multiple RTKs (Chandarlapaty et al. 2011). Moreover, inhibition of MEK 
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in basal-like breast cancer also caused activation of RTKs, precluding a response to single-
agent MEK inhibitors in vivo (Duncan et al. 2012). 
In follow-up studies, we plan to delve further into the metastatic phenotype as much 
remains to be explored. By taking advantage of the secondary transplantation and in vitro 
culture systems that were established, it would be very interesting to examine how each site 
of dissemination exerts unique requirements for successful metastasis and how those sites 
may differ, or not, in their responses to the reactivation of Pten. The dual-fluorescent 
reporter system allows us to easily track the relevant disseminated cells and continue to 
monitor their activity even after the shRNA has been shut off. This element of our mouse 
model offers us many new experimental possibilities.  
Finally, the novel allelic combination of WAP-Cre and RIK to drive the shRNA 
transgene has yielded reproducible and clean results, and we believe that we have been able 
to build a robust model that will be essential in the validation of novel tumor suppressor 
genes, such as Nf1, that will be identified in larger screening efforts in the future. 
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V. Conclusions and Future Perspectives 
 
Diversity and complexity are hallmarks of the cancer genome (Hanahan and 
Weinberg 2000; Hanahan and Weinberg 2011). Even in cancer types where clear driving 
oncogenes have been identified, a complex web of additional genetic lesions help to 
facilitate the uncontrolled expansion and eventual metastasis of the tumor. As a 
consequence, the behavior of individual tumors is heterogeneous and remains difficult to 
predict. The advent of sophisticated array and sequencing technology has exposed the 
complexity of the cancer genome; yet functional studies are required to determine the 
impact of different genetic configurations on cancer progression and to identify the unique 
vulnerabilities they create.  
The vast majority of published studies use cell culture models to examine the effects 
of specific genes on the processes of disease initiation, progression and maintenance, as well 
as response to therapy. Undoubtedly, certain aspects of the transformed phenotype can be 
mimicked in cell culture, but cancer is fundamentally a disease of the whole organism. In 
addition to the vast complexity of multiple cellular mechanisms, cancerous disease is 
influenced significantly by the cellular microenvironment, a fact that has been extensively 
documented in breast cancer (Egeblad et al. 2010; Polyak and Kalluri 2010). Therefore, while 
in vitro approaches can uncover and characterize certain important and novel details, 
ultimately their relevance must be verified in vivo. In addition, in vivo models provide a 
robust means to identify novel mechanisms involved in the malignant progression of 
cancer, both at the physiological and molecular level, which is critical towards a better 
understanding of metastasis, the form of disseminated disease that is the main cause of 
death in human breast cancer patients.  
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However, such studies, particularly those involving relevant in vivo experimentation, 
have been slow, expensive, and often unable to efficiently model the diversity of human 
breast cancer subtypes in a way that allows for conclusive and meaningful insights. A major 
goal of our efforts described in this thesis has been to speed up these analyses through the 
development and adaptation of innovative research methodology, such as the RNAi 
technology pioneered by our laboratory, to explore the biology of tumor suppressor genes. 
A major goal of the work described in Chapter 2 was the development of an 
orthotopic transplantation model that would be well adapted for high-throughput 
screening, and we aimed to be able to search for novel TSGs or oncogenes through in vivo 
positive selection of virally introduced constructs. Our first setback was in the choice of cells 
for transplantation. Previous efforts in the lab to produce mosaic models of different cancer 
types had relied on the isolation of tissue progenitor cells, such as hematopoietic stem and 
progenitor cells or hepatoblasts, that can be readily cultured and re-transplanted into 
recipients (Zender et al. 2008; Bric et al. 2009; Zuber et al. 2009; Zuber et al. 2011b; Scuoppo 
et al. 2012). This approach has the advantage of developing physiologically relevant mouse 
models of cancer without the burden of producing and crossing many germ line mutant 
strains, complementing the transgenic methods such as those discussed in Chapters 3 and 4. 
However, while we were able to harvest primary mammary progenitor cells capable of 
differentiating into a fully branched ductal epithelium, we were unsuccessful in isolating 
and propagating these cells at sufficient numbers to produce a tractable and affordable 
mosaic model for large-scale studies. In future iterations of such a screening project, we 
hope to circumvent these technical difficulties and perhaps adopt the methodology of 
combining in vitro screens utilizing human cell lines with individual hit validation in mouse 
models. Our identification of NF1 as a putative novel tumor suppressor, nonetheless, 
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confirms that the fundamental strategy of mining human patient copy number variation 
data for deleted chromosomal regions for subsequent filtering through the mouse remains 
an efficient way of finding relevant driver genes.  
When this positive selection screen was first conceived, the concept of molecular 
profiles of human breast cancer subtypes was only just emerging. If we were to repeat this 
project again we would undoubtedly segregate the patient tumor samples into the 
appropriate molecular categories, provided sufficient numbers could be gathered to achieve 
statistical significance. Combining this refinement of the candidate cancer gene lists with 
additional knowledge regarding the predicted cells-of-origin and the sensitizing oncogenes 
most relevant to each subgroup would allow us to conduct screens with more sophistication 
and an increased likelihood of achieving clinical relevance.  
Chapter 3 described the development of a multi-alleleic RNAi mouse model that 
utilizes a novel combination of both established and newly generated genetically engineered 
mouse strains. In Chapter 4, this model was then applied to the study of the role of PTEN in 
HER2 positive breast cancer, and we characterized the aggressive, highly metastatic disease 
phenotype observed. The cooperation of PTEN knockdown and NeuNT overexpression in 
the luminal mammary epithelium was almost too efficient, as we observed highly 
proliferative and multifocal tumor growth, but the model system proved robust and a 100% 
penetrance of mammary tumor development was documented in TG-shPTEN animals. 
Since spontaneous metastasis to multiple organ sites is a rare feature in most animal models 
of cancer, further studies to test the differential requirement for cellular transformation 
required for efficient homing to and growth in the lung, liver and bone niches may provide 
important answers. Techniques such as barcoding or single-cell whole genome sequencing 
could be powerful in furthering our understanding of critical details such as the clonality of 
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the primary and metastatic tumorigenic processes, the timing of circulating tumor cell 
shedding and the potential role of self-seeding in tumor evolution, or the relationship 
between cellular changes that occur in the primary versus distal niches and their 
contribution to the transformative selection and growth (Kim et al. 2009; Navin et al. 2011). 
Finally, to maximize the potential of the multi-allelic mouse model such as the one 
described here for the assessment of gene function in vivo, we hope to expand our 
methodology to include the re-derivation of ESCs and further apply ex vivo manipulation to 
introduce inducible, reversible alleles (shRNAs, cDNAs, microRNAs) to the ColA1 locus. 
The ultimate goal is to make breast cancer mouse modeling a more rapid, flexible, and 
scalable platform where multiple combinations of cooperating genetic legions can be 
analyzed in parallel and the effects of tissue-specific transient gene activation or inhibition 
can be easily assessed at different stages of disease using the inducible, reversible alleles. 
Such models increase our capacity to physiologically filter through the vast quantities of 
oncogenomic data being produced, for which the biological impact remains largely 
uncharacterized. While xenograft models are an effective means of propagating human 
cancers and capturing their unique complexity, well-defined and sophisticated GEMMs 
present a genetically tractable arena in which sporadic and de novo tumorigenesis can be 
studied in an immunologically competent organism.  
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VI. Materials and Methods 
ROMA breast cancer data set 
Representational Oligonucleotide Microarray Analysis (ROMA) was conducted as 
previously described (Lucito et al. 2003; Hicks et al. 2006). Pinning analysis was conducted 
on ROMA data from 247 frozen breast tissue samples: 139 from the Karolinska Institute in 
Stockholm, Sweden, and 118 from the Radium Hospital in Oslo, Norway. The deletion 
size/frequency analysis was performed on those 247 samples plus ROMA data from 43 
human breast cancer cell lines.  
shRNA library production 
BIOPREDsi was used to design shRNA sequences (Huesken et al. 2005). 125-bp 
oligonucleotides encompassing the whole stem-loop miR-30 shRNA precursor, flanked by 
EcoRI and XhoI cloning sites were ordered from Agilent (Santa Clara, CA), and amplified 
with a library-specific reverse primer (for main library: TTCTGCAAGGCCTCCAGGTTGG, 
for priority set:  TTCACGATCTGCTGCAGAATGTGTCT) and a common forward primer 
(miRXhoF: TACAATACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG). Pooled 
cloning was conducted as described (Zuber et al. 2011a; Scuoppo et al. 2012). To avoid the 
introduction of oligonucleotides with synthesis errors, such as mutations introduced during 
PCR amplification steps or concatemerization of inserts during vector ligation, each unique 
shRNA vector was verified by sequencing before inclusion in the resulting library. Clones 
were miniprepped and sequenced in 96-well format.  
Viral constructs 
shRNA vectors – MLS and MLP (LMP) miR-30 based shRNA vectors were cloned as 
previously described (Dickins et al. 2005). For MLR, the GFP cDNA was replaced with 
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dsRed cDNA. shRNAs were designed using the BIOPREDsi algorithm (www.biopredsi.org, 
discontinued) (Huesken et al. 2005), PCR amplified from oligos, and cloned into the miR-30 
backbone as described using XhoI/EcoRI restriction sites (Zuber et al. 2011a). 
Oncogene vectors – MultiSite Gateway® Cloning Technology (Invitrogen 
Technologies) was use to make all lentriviral plasmid vectors, including UbC-NeuNT, 
CMV-NeuNT and all other oncogene cDNA overexpression vectors employed. These 
vectors contained a blasticidin resistance marker. 
Cell lines 
Comma-D cells were obtained from Senthil Muthuswamy. NMuMG cells were 
purchased from ATCC (Catalog # CRL-1636). 
Cell culture 
Retroviral transfections/infections – For calcium phosphate transfection, 6x106 phoenix 
cells were plated in 10cm plates 6 to 12 hours prior to transfection with 15µg shRNA 
construct and 5 µg ecotropic helper plasmid (McCurrach and Lowe 2001). Fresh media was 
added 12 hours after transfection and viral supernatant was collected twice at 36 and 48 
hours post-transfection. Viral supernatant was filtered through a .45µm filter, then diluted 
1:2 with fresh media and supplemented with polybrene (4µg/mL final conc.) for a single 
infection of target cells. Target cells (NMuMG, Comma-D) were split 1:3 from confluent 
plates 12~24 hours prior to second virus collection. Infection rates were determined using 
GUAVA flow cytometers (Millipore, Billerica, MA).  
Lentiviral transfections/infections – Similarly, for lentiviral calcium phosphate 
transfections, 293FT cells were plated for transfection density 8x106 cells per 10cm plate. 
10µg plasmid DNA was combined with 3.5µg VSVG, 2.5µg REV and 6.5µg MDL helper 
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constructs during transfection. After collection of the viral supernatant, it was centrifuged 
prior to filtration in order to remove the large quantity of cell debris.  
ESC targeting and culture 
ColA1-targeting constructs were cloned as described (Premsrirut et al. 2011; Dow et 
al. 2012). TREtight promoter modified version was previously described (McJunkin et al. 
2011). KH2 ESCs were targeted by electroporation of 50µg of targeting construct with 25µg 
pCAGGs-Flpe as described (Premsrirut et al. 2011; Dow et al. 2012). ESCs were cultured on 
irradiated DR4 fibroblast feeder layers on gelatinized plates in M15 media containing LIF as 
described (Beard et al. 2006).  
Primary mammary gland harvest and isolation of MaSCs 
Isolation of primary murine mammary stem/progenitor cells was conducted as 
previously described (Shackleton et al. 2006). Briefly, 8 to 14 week old mice were euthanized 
by CO2 inhalation, followed by cervical dislocation. A midline incision of the skin was 
performed and the mammary fad pads were exposed. The mammary glands were excised 
and placed into mammary gland digestion medium. Crude epithelial organoids were 
obtained by incubating the mammary glands in digestion medium for 6 to 8 hours at 37 °C 
with hourly pipetet-mixing and vortexing. A single cell suspension of mammary epithelial 
cells was obtained by sequentially digesting the organoids with Trypsin/EDTA, dispase 
and DNAse and trituration using fire-polished glass pasteur pipettes. The resulting cell 
suspension was filtered through a 40um cells strainer and cells were plated into growth 
medium on ultra-low attachment tissue culture plates. 
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in vivo animal studies 
The Institutional Animal Care and Use Committees of Cold Spring Harbor 
Laboratory and Memorial Sloan-Kettering Cancer Center approved all mouse experiments 
conducted in their respective animal facilities.  
Orthotopic transplantation into mammary fat pads 
Orthotopic transplantations were conducted as follows: the mouse was anesthetized 
with isoflurane (1-4%) administered with a precision vaporizer. Depth of anesthesia was 
monitored at least every 10 minutes throughout the procedure by observing that there was 
no change in respiratory rate associated with surgical manipulation. Following confirmation 
that a suitable anesthetic plane (no response to stimulation) has been attained, the fur 
covering the lower abdominal area was removed (unless conducting surgery on a nude 
mouse) with an electric clipper with a #40 blade exposing an area of skin approximately 
150% larger than the area of the incision and sterile eye lubricant was applied to both eyes to 
prevent corneal drying during surgery. Loose fur was removed with a moist gauze pad. A 
small volume (0.1-0.2cc) of local anesthetic agent, such as bupivacaine (Marcaine 0.25-0.5%), 
was infiltrated into the tissue adjacent to the intended incision line. The mouse was placed 
on a circulating water heating pad and covered with a drape. The area was then prepped for 
surgery using three rounds of alternating scrubs of 10% povidone-iodine and 70% ethanol 
soaked gauze sponges. The skin was then painted with a 10% povidone-iodine. All surgical 
instruments and equipment were sterilized by steam sterilization prior to surgery and 
sterilized between individuals using a glass bead sterilizer. The animal, which was 
positioned in the supine position, was covered with sterile surgical crepe paper. A 3.0 cm x 
3.0 cm square hole that has been cut into the drape was located over the intended incision 
site. Sterilized surgical scissors were used to make an incision in the abdominal region that 
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penetrates the skin but not into the peritoneal cavity. The opening was be enlarged 
vertically and horizontally in order to expose the abdominal mammary fat pads of the 
mouse. To avoid drying of the exposed tissue, each flank of the animal was manipulated in 
sequential order. In some cases the fat pad was cleared, removing all of the tissue before the 
lymph node. The fat pad was then injected with cells (primary or cell line), tumor (fragment 
or digested) or virus (Adeno) using a syringe. The volume ranged from 10 to 20µL. After 
both abdominal fat pads were manipulated, the skin was be brought together and closed 
using sterile 4-0 or 5-0 vicryl sutures or surgical glue or both. After surgery, animals were 
observed until they could maintain sternal recumbency. Before being returned to the 
housing area, they were administered 1 mg/kg buprenorphine, SQ. They were evaluated at 
least one additional time the day of surgery and at least daily for the next 48 hours. Tumor 
progression was monitored by in vivo fluorescence imaging, palpation and/or caliper 
measurements depending on the assay. 
Immunohistochemistry 
Immunostaining was conducted on a Discovery Ultra automated device (Ventana) 
with the following antibodies and concentrations: GFP (Cell Signalling 2956,1:200), tRFP (for 
mKate2; Evrogen AB233, 1:5000), ErbB2 (for Neu; Abcam ab2428, 1:500), PTEN (Cell 
Signaling 9559, 1:100), Ki-67 (Abcam 16667,1:100), CK5 (Covance PRB-160P, 1:10000), CK14 
(Covance PRB-155P, 1:1000), CK19 (Abcam ab15463, 1:100), TTF1(Novus Biologicals,1:100). 
Primary antibodies were applied at room temperature for 3 hours and secondary antibody 
from goat source (Vector Laboratories) was applied at 1:300 at 37,C for 20 minutes. 
Streptavidin-biotin peroxidase-based DAB Map Detection Kit (Ventana 760-124) was used 
and slides were counterstained with Hematoxylin (Ventana, 760-2021) and Bluing Reagent 
(Ventana, 760-2037). 
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Doxycycline treatment 
Cell culture – All dox-containing media was prepared at a dose of 1µg/ml 
doxycycline (Sigma-Aldrich, St. Louis, MO). 
Animal studies – Mice were treated with doxycycline hyclate at a dose of 625mg/kg 
in alfalfa-free rodent diet with 18.2% protein, 48% carbohydrate and 5.8% fat content 
(Harlan Laboratories, Madison, WI). The diet is designed to deliver a daily dose of 2-3mg of 
doxycycline based on consumption of 4-5g/day by a mouse; doxycycline hyclate contains 
approximately 87% doxycycline. Since the chlorophyll from the alfalfa found in standard 
mouse food has been found to fluoresce in the near infrared part of the spectrum; we used 
alfalfa-free dox chow in our experimentation (Troy et al. 2004; Inoue et al. 2008). 
Adenoviral Cre 
Adeno-Cre virus was purchased commercially from the Gene Transfer Vector Core 
of the University of Iowa. A 10µL volume was injected into the fat pad at a dose of 109pfu. 
!  
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Table 6.1  shRNA sequences 
shRNA  
(Prediction algorithm) 
Sequence 
Renilla-Luciferase.713 
(BIOPREDsi) 
CTCGAGAAGGTATATTGCTGTTGACAGTGAGCGCAGGAAT
TATAATGCTTATCTATAGTGAAGCCACAGATGTATAGATA
AGCATTATAATTCCTATGCCTACTGCCTCGGAATTC 
 
Luciferase.1309 
(Codex) 
CTCGAGAAGGTATATTGCTGTTGACAGTGAGCGCCCGCCT
GAAGTCTCTGATTAATAGTGAAGCCACAGATGTATTAATC
AGAGACTTCAGGCGGTTGCCTACTGCCTCGGAATTC 
 
Pten.1522 
(BIOPREDsi) 
CTCGAGAAGGTATATTGCTGTTGACAGTGAGCGACCAGCT
AAAGGTGAAGATATATAGTGAAGCCACAGATGTATATATC
TTCACCTTTAGCTGGCTGCCTACTGCCTCGGAATTC  
 
Pten.2049 
(BIOPREDsi) 
CTCGAGAAGGTATATTGCTGTTGACAGTGAGCGAAAGATC
AGCATTCACAAATTATAGTGAAGCCACAGATGTATAATTT
GTGAATGCTGATCTTCTGCCTACTGCCTCGGAATTC 
 
Nf1.6074 
(BIOPREDsi) 
CTCGAGAAGGTATATTGCTGTTGACAGTGAGCGACAGATG
TATCCTTCTATTCAATAGTGAAGCCACAGATGTATTGAATA
GAAGGATACATCTGCTGCCTACTGCCTCGGAATTC  
 
Nf1.8594 
(Codex) 
CTCGAGAAGGTATATTGCTGTTGACAGTGAGCGAGCTGGC
AGTTTCAAACGTAATTAGATGAAGCACAGATGTAATTACG
TTTGAAACTGCCAGCGTGCCTACTGCCTCGGAATTC  
 
Nf1.9930 
(BIOPREDsi) 
CTCGAGAAGGTATATTGCTGTTGACAGTGAGCGCCTCAGTT
AAGATTGAACTATATAGTGAAGCCACAGATGTATATAGTT
CAATCTTAACTGAGATGCCTACTGCCTCGGAATTC  
 
*shRNA sequences are listed as full length 116nt XhoI/EcoRI fragments for miR-30 cloning. 
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Table 6.2  Genotyping PCR primer sequences 
Transgenic allele  Primers 
Renilla-Luciferase.713 
(shRNA specific) 
5' GTATAGATAAGCATTATAATTCCTA 
5' GAAAGAACAATCAAGGGTCC 
Pten.1522 
(shRNA specific) 
5' CAGATGTATATATCTTCACCTTT 
5' CACCCTGAAAACTTTGCCCC 
Nf1.6074 
(shRNA specific) 
5' GCCACAGATGTATTGAATAGAA 
5' GAAAGAACAATCAAGGGTCC 
Nf1.8594 
(shRNA specific) 
5' CCACAGATGTAATTACGTTTGA 
5' CACCCTGAAAACTTTGCCCC 
ColA1 locus 
Targeted/wild type 
5’ AATCATCCCAGGTGCACAGCATTGCGG 
5’ CTTTGAGGGCTCATGAACCTCCCAGG 
5’ ATCAAGGAAACCCTGGACTACTGCG 
ColA1 locus 
Targeted/empty CHC 
5' AATCATCCCAGGTGCACAGCATTGCGG 
5' GGATGTGGAATGTGTGCGAG 
5' CTTTGAGGGCTCATGAACCTCCCAGG 
Rosa26 locus 
(for RIK or R26-rtTA2) 
5’ AAAGTCGCTCTGAGTTGTTAT 
5’ GCGAAGAGTTTGTCCTCAACC 
5’ GGAGCGGGAGGAATGGATATG 
WAP-Cre 
Presence/absence 
5' CTAGGCCACAGAATTGAAAGATCT 
5' GTAGGTGGAAATTCTAGCATCATCC 
5' GCGGTCTGGCAGTAAAAACTATC 
5' GTGAAACAGCATTGCTGTCACTT 
MMTV-NeuNT 
Presence/absence 
5' CCCCGGGAGTATGTGAGTGA 
5' TGAGCTGTT TTGAGGCTGCA 
CAGs-rtTA3 
(“4288”) 
5’ TGCCTATCATGTTGTCAAA 
5’ CGAAACTCTGGTTGACATG 
5’ CTGCTGTCCATTCCTTATTC 
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Table 6.3  Transgenic mouse strains 
Strain Reference 
Renilla-Luciferase.713 TRE promoter: Premsrirut et al. 2011 
TREtight promoter: unpublished 
Pten.1522 Miething, et al., In preparation 
Pten.2049 Miething, et al., In preparation 
Nf1.6074 Unpublished 
Nf1.8594 Unpublished 
Rosa26-rtTA-M2 Hochedlinger et al. 2005 
MMTV-tTA Hennighausen et al. 1995 
RIK Unpublished  
WAP-Cre Wagner et al. 1997 
MMTV-NeuNT Muller et al. 1988 
CAGs-rtTA3 “4288” Premsrirut et al. 2011 !  
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Appendix. Differential expression of TRE and TREtight promoters 
 
In order to assess differences in the promoter expression patterns and levels between 
TRE and TREtight, a number of age-matched mice were treated with doxycycline and 
harvested side-by-side. GFP reporter expression as observed by gross examination using 
fluorescence microscopy. The spleen, kidney, liver, small intestine, colon, skin, pancreas, 
stomach, lung, heart and thymus were examined and GFP expression levels were 
documented. Brightfield and GFP images are shown for each organ type in the Appendix 
figures. 
 
The first cohort of mice was designed to compare single vs. double copy of the 
Rosa26-rtTA2 allele using TREtight-GFP-shRLuc.713 and TREtight-GFP-shNF1.8594 
littermate female mice. Dox treatment was started at 4 weeks of age for 18 days. An age-
matched wild type control mouse was included (no dox treatment).  
 
The second cohort sought to compare both single-copy R26-rtTA2 with CAGs-rtTA3 
(“4288”), as well as TRE-GFP-miR30 vs. TREtight-GFP-miR30. The following mice were dox 
treated starting at 6 weeks of age for 16 days:  
• CAGs-rtTA3 ; TtG-shRLuc (2 mice) and TtG-shRLuc only (1 mouse) littermates 
• R26-rtTA2+/- ; TtG-shNF1.6074 (2 mice) and TtG-shNF1.6074 only (1 mouse) littermates 
• CAGs-rtTA3 ; TG-shAPC.9365 (1 mouse) 
 
The following mice were dox treated starting at 11 weeks of age for 2.5 months: 
• R26-rtTA2 ; R26-Luciferase ; TG-shLuci.1309 on dox (two mice) 
• R26-rtTA2 ; R26-Luciferase ; TG-shLuci.1309 off dox control (one mouse) 
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